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Abstract:  
 
The neuroanatomical structures underlying Major Depressive 
Disorder (MDD) are not fully understood. Invasive treatment options 
now exist that target the brain structures associated with MDD.  
In part one of this study, the effects of MDD on emotion 
processing are being measured and discussed. Emotion processing 
was examined in patients with chronic, treatment resistant 
depression (n = 15) and a healthy control group (n = 38). Emotion 
processing abilities were impaired in the MDD group, especially 
those of disgust recognition. 
In part two, seven of the fifteen MDD patients that had received 
an Anterior Cingulotomy (ACING) and eight of the fifteen MDD 
patients that had received a Vagus Nerve Stimulation (VNS) as an 
intervention for chronic, treatment resistant depression were 
presented with the same series of emotional processing tasks given 
in part one. Their post surgical performance was compared with their 
pre surgical performance. After surgery, the ACING group showed 
decreased emotion processing abilities and the VNS group showed 
improvements. 
Findings suggest that emotional functions assumed to be 
associated with certain neural structures that are adversely affected 
in patients with MDD may be responsible for some of the clinical 
features of MDD.  
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1 Introduction 
Major Depressive Disorder (MDD) is ranked by the World Health 
Organisation (WHO) as the number one leading cause of disability (WHO, 
2001). It is estimated that MDD affects at least 10% of the world’s 
population (McKenna, 2005). In the United States alone, the economic cost 
to individuals, society, and the health system due to MDD was $150 billion 
in 1996 (Hirschfeld, 1998). Every year, depressed individuals report on 
average 35 days in which they are unable to work or carry out normal 
activities (Rush, 2007). These facts stress the importance of further research 
and understanding of MDD with the aim of developing effective treatment 
strategies. 
MDD is considered a neuropsychological syndrome that arises from 
disordered processing in neural networks that modulate normal emotional 
behaviour (Mayberg, 2005; Mayberg, 1997; Nemeroff 2002; Nestler, 2002). 
The aetiology of this abnormal processing is not completely agreed upon, 
but converging findings concur that irregular synthesis, secretion, and 
concentrations of fundamental neurotransmitters, hormones, and growth 
factors can trigger atrophy to specific neural structures. Neuroanatomical 
volume reductions, abnormal metabolic activity, and differences in neuron 
size and concentration in the depressed brain have been observed in 
neuroimaging studies as well as in post-mortem anatomical investigations1. 
These neural abnormalities alter the cognitive and emotional abilities of 
those affected with MDD, and are associated with the signs and symptoms 
of the disorder2. Below average performance is common on emotional and 
cognitive tasks administered to MDD patients. It has been hypothesized that 
impaired emotional processing may be the leading cause of social 
dysfunction among depressed patients (Surguladze, 2004).  
Although current antidepressant medication and psychotherapy are 
viable treatment options for some patients with MDD, only 50% to 60% 
respond to any one medication and only 35% of patients become symptom 
free (Kupfer, 2003). Relapse of depressive symptoms is the norm in the 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
1 see section 1.2.3 
2 see section 1.4	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majority of depressed patients (Warden, 2007). Approximately 20% of those 
who have depression are resistant to medications and psychotherapy and are 
termed ‘treatment resistant’ patients (Malone, 2010). Due to the disabling 
symptoms, chronic nature, high relapse rates, wide prevalence, and societal 
costs associated with MDD, it is vital to further explore the 
neurophysiology, neuropsychology, and novel treatment options of the 
condition. 
Invasive treatment options exist that target the brain structures 
associated with MDD. The two invasive treatment options focused on in this 
thesis are Vagus Nerve Stimulation and Anterior Cingulotomy3. After these 
neurosurgical interventions are performed on a patient with MDD, 
metabolic activity has been observed to revert back to that expected in a 
healthy brain. In certain cases, emotional and cognitive deficits subside4. 
Research has recently begun to identify the effects of these invasive 
procedures measured by scores on emotion processing tasks. These tests of 
emotional recognition are administered both before surgery takes place, to 
establish a baseline, and after surgical intervention to measure effects on 
performance.  
With the aim to identify affected neural areas that contribute to 
symptoms of MDD, an established structure–function relationship was used 
as a behavioral marker to infer the possible involvement of specific neural 
substrates (Sprengelmeyer et al., 2011). Specifically, recent meta-analyses 
show agreement from large bodies of research that link certain brain areas 
with the processing of specific emotions5. By observing if certain emotion 
processing tasks are impaired among individuals with MDD, inferences can 
be drawn to which brain structures are functionally impaired as well. 
In Part One of the study, the ability of a group with MDD to identify 
emotional information was determined. Deficits in functional recognition of 
particular emotions can suggest specific abnormal brain structures. With this 
information, hypotheses can be made to which structures are being affected 
by MDD and may play a role in the major symptoms of the disorder. 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
3 see section 1.3.3.2 and section 1.3.3.3  
4 see section 1.3 
5 see section 1.4.3 
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In Part Two, scores from emotional tests6 administered before and after 
Vagus Nerve Stimulation and Anterior Cingulotomy are compared. 
Statistical analysis is performed on patient’s performance before and after 
therapeutic surgery to determine if emotion processing abilities have been 
altered due to treatment—or not. As many facets of the surgeries are in fact 
permanent, it is important to discover what effects these neurological 
procedures have on a patient’s cognitive abilities (Ridout, 2007).  
The theoretical part of this thesis describes the aetiology, clinical 
symptoms, epidemiology, historical approaches, contemporary approaches, 
neuroanatomical approaches, neurosurgical treatment options, and 
neuropsychology of Major Depressive Disorder. Building on this corpus of 
data, two topics are investigated in a behavioural study: the effect of MDD 
on emotion recognition and the side effects of invasive neurosurgery on 
emotion processing. The outcomes of these investigations will highlight the 
efficacy of new invasive treatment options for MDD, as well as the general 
effect that MDD has on a patient’s ability to process emotional information. 
 
 
 
1.1 Major Depressive Disorder 
1.1.1 Aetiology 
Depression can occur idiopathically (Krishnan, 2009) with no obvious 
external cause. However, certain life events, medications, and health 
conditions are closely linked with the prevalence of MDD. Divorce and 
childhood abuse are among the environmental risk factors most associated 
with depression (Palosaari, 1996; Kendler, 2004). Particular endocrine 
abnormalities such as hypothyroidism and hypercortisolism are also 
associated with depression. Cancers such as pancreatic adenocarcinoma and 
breast tumours are tied to depression as well. Furthermore, certain 
medications such as isotretinoin, used to treat acne, as well as interferon-α, 
used to treat hepatitis C, have been shown to significantly increase the risk 
of developing MDD (Evans, 2005). High instances of depression are also 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
6 see section 2.2.2	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found in neurological illnesses that cause cell death in brain areas associated 
with emotional functioning7  (Sheline, 2003). These illnesses include 
Huntington’s disease, post-stroke syndromes, Alzheimer’s disease, epilepsy, 
and Parkinson’s disease. 
Although no one single “depression gene” has been isolated that could 
help to definitively diagnose depression, many studies have explored genetic 
polymorphisms involved in monoaminergic transmission (Levinson, 2006). 
For example, if one acquires two short alleles for the serotonin transporter 
gene they are more vulnerable to develop depression after experiencing 
stressful life events (Caspi, 2003). It seems that individuals possess a genetic 
‘stress threshold’ which determines how one reacts to stress and whether 
this reaction can lead to the development of depression8. 
 
1.1.2 Clinical Description 
1.1.2.1 Diagnostic and Statistical Manual of Mental Disorders 
IV (DSM-IV) Definition 
The DSM-IV defines MDD as a disorder characterised by sad mood or 
the loss of pleasure in day-to-day activities. In addition, four of the 
following criteria must be met as well: sleeping too much or too little; 
psychomotor retardation or agitation; poor appetite and weight loss, or 
increased appetite and weight gain; loss of energy; feelings of 
worthlessness; difficulty concentrating, thinking, or making decisions; and 
recurrent thoughts of death or suicide. These symptoms must be present for 
at least two weeks every day for most of the day. Finally, these symptoms 
cannot be due to normal bereavement. 
 
1.1.2.2 Clinical Presentation of the Disorder 
1.1.2.2.1 Overview 
MDD is a multifaceted disorder that disrupts mood, cognition, 
sensorimotor, and homeostatic/drive functions (including those that control 
sleep, appetite, and libido) (Mayberg, 2009). Clinical complaints common 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
7 see section 1.2.3 
8 see section 1.2.2.2.2	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among MDD patients include impaired concentration, memory, and 
attention (Delgado, 2009). Patients with depression express difficulty in 
experiencing pleasure, have both slowed thought processes and movement, 
psychological pain (an awareness of negative changes in the self, 
accompanied by negative feelings), dysphoric mood, suicidal ideation, and 
predisposition to ruminating about past events (Giacobbe, 2009; Orbach et 
al., 2003). The symptoms of depression are debilitating—depressed 
individuals report a mean of 35 days a year when they were totally unable to 
work or carry out normal activities (Rush, 2007).  
Depressive episodes can last anywhere from weeks to years and should 
not be thought of as isolated events. After reaching remission from 
depressive symptoms, two thirds of individuals are expected to experience a 
relapse of depressive symptoms at least once within their lifetime (Solomon, 
2000). On average, four episodes of depression are experienced (Judd, 
1997). In a study performed by Solomon et al. (2000) it was observed that 
with every episode, one’s risk for experiencing a relapse episode increased 
by 16%. 
In addition to experiencing harmful day-to-day symptoms, patients with 
MDD have higher mortality rates associated with comorbid conditions. For 
example, a 2.3 fold increase in mortality occurs in MDD patients with type 2 
diabetes, an eightfold increase is seen in congestive heart failure patients, 
and a 2.6 fold increase in mortality is seen in individuals with coronary heart 
disease (Katon, 2005; Barth, 2004). It has been noticed that patients with 
MDD have lower bone density and increased risk for cardiovascular 
problems (Cizza, 2011).  
Increased rates of suicide are absolutely related with MDD. Based on a 
meta-analysis performed by Botswick et al. (2000), in outpatients with less 
severe depression, suicide rates are around 2.2%. However, in individuals 
with severe depression who have been hospitalized for previous attempted 
suicide, suicide rates are as high as 8.6% (Bostwick, 2000). 
Although depression is diagnosed in a symptom-based manner 
dependent upon clinical presentation, two depressed individuals may only 
share one symptom in common. Because of this, a wide variety of clinical 
presentations exist for the syndrome (Drevets, 2001).  Given the differences 
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in presentation of depressive symptoms, five MDD subgroups have emerged 
and are discussed below. 
 
1.1.2.2.2 A-Typical Depression 
As soon as the first generation of antidepressants were introduced to the 
market in the 1950s, physicians began to recognize a certain type of 
depressed patient that responded especially well to Monoamine Oxidase 
Inhibitors (MAO inhibitors). This subgroup includes 15% to 29% of all 
people with MDD and is named ‘a-typical depression’ (Thase, 2007). The 
clinical presentation includes hypersomnia, interpersonal sensitivity, leaden 
paralysis, increased appetite and/or weight, and phobic anxiety (Thase, 
2007). 
 
1.1.2.2.3 Melancholic Depression 
Melancholia is the oldest documented form of depression. Individuals 
with melancholia cannot trace their depression to a reaction towards life 
stressors. To qualify for this subtype, either anhedonia or lack of mood 
reactivity must be present as well as three of the following: depression that 
is not secondary to grief or loss, severe weight loss or loss of appetite, 
psychomotor agitation or retardation, early morning awakening, guilt that is 
excessive, and worse mood in the morning (DSM-IV text revision, 2008). 
The ability to experience pleasure is seemingly lost; this anhedonia is not 
improved by positive external events (Biro, 1989). Biological markers are 
present to aid in the diagnosis of melancholia. The most prominent markers 
are shortened eye movement latency and excessive cortisol secretion (Rush, 
1997). Medication is especially effective compared to placebo when treating 
melancholic patients (Rush, 1998). 
 
1.1.2.2.4 Psychotic Depression 
Delusions as well as hallucinations that match one's mood are symptoms 
of psychotic depression. 18% of MDD patients could be diagnosed as 
psychotic, and usually represent only those individuals suffering from 
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severe depression (Ohayon, 2002). Due to hyperactivity in the 
Hypothalamic-Pituitary-Adrenal (HPA) axis9, elevated serum cortisol levels 
are found in those with psychotic depression (Coryell, 1996). On a cognitive 
level, impaired verbal memory and executive functioning is observed 
(Fleming, 2004). Electroconvulsive therapy is especially effective in the 
treatment of psychotic depression; however, most individuals with 
treatment-resistant depression show characteristics of psychotic depression 
(Coryell, 1996). 
 
1.1.2.2.5 Anxious Depression 
Anxious depression includes depressive symptoms that are comorbid 
with an anxiety disorder (Rush, 2007). Patients with anxious depression are 
usually severely depressed and are at a high risk to have recurrent thoughts 
about death and suicide. Other clinical symptoms associated with anxious 
depression are hypochondriasis and persistent residual anxiety even after 
being treated with antidepressants (Rush, 2007). 
 
1.1.2.2.6 Treatment Resistant Depression (TRD) 
In general, the failure to respond to four full trials of antidepressants 
consisting of the correct dose and duration as well as failure to respond to 
electroconvulsive therapy classifies a patient as having TRD (Shields, 
2008). More specifically, a treatment has failed if no response is detected 
when a treatment is administered for at least four weeks, except in the case 
of electroconvulsive therapy (Nahas, 2006). TRD patients represent 10% to 
20% of all individuals with MDD (Shields, 2008). In the case of TRD 
patients, neurosurgery is often their only viable treatment option. 
 
1.1.3 Epidemiology 
1.1.3.1 Prevalence 
Differences in criteria used to generate diagnoses and methodologies 
used in prior studies estimate an overall lifetime prevalence rate of MDD 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
9 see section 1.2.2.2.3 
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from 4-20% (Andrade, 2003). The age of onset for depression is usually in 
the early to mid-twenties (Andrade, 2003). In an international study 
including almost 38,000 people, it was discovered that rates of depression 
are also affected by which country one lives in. For example, in Taiwan only 
1.5% of the population is depressed, while in Beirut depression rates are 
reported to be as high as 19% (Weissman, 1996). This could be explained by 
differences in distance from the equator, and thus the amount of sunlight one 
receives. Others hypothesize that the reason for differential rates is tied to 
culture and national customs (Weissman, 1996). However, no matter where 
an individual with MDD is from geographically, they are always more likely 
to abuse alcohol and other substances.  
Many health related patterns exist pertaining to MDD. For example, 
MDD occurs about twice as often in women as in men (Kring, 2010). Rates 
are higher in the unmarried than in the married, with rates especially high in 
divorced individuals (Andrade, 2003). Socioeconomic factors are also 
pertinent, as MDD is three times more common among people who are 
impoverished than in those who are not (Kessler, 2005). 
 
1.1.3.2 In Children and Adolescents  
Recently, more and more evidence seemingly indicates that incidence of 
depression among people under twenty is on the rise. From 1987 to 1996, 
data were collected from over 900,000 American youths (Zito, 2003). This 
study detected that in those 10 years, the amount of antidepressants 
prescribed to individuals under the age of 20 increased tenfold. However, 
according to Costello et al. (2006), increases in medication prescribed at the 
moment can be explained by better diagnosis by physicians. The willingness 
to prescribe antidepressant medications may also have increased in recent 
years, as well as the number of pharmacologic treatment options.  
Additionally, suicide rates among the age range of 5-19 have increased 
from the 1950s to the 1990s (Centre of Disease Control). A British study 
conducted over 25 years reported similar results (Collishaw, 2004). The 
study utilized data from emotional health surveys administered in hospitals 
and observed that in boys, emotional problems increased from 7.8% in 1974 
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to 13.3% in 1999. In girls, emotional problems increased from 12.8% in 
1974 to 20.4% in 1999; overall, emotional problems increased from 10.2% 
in 1974 to 16.9% in 1999.  
 
1.1.3.3 In the Elderly 
MDD affects up to 4% of the elderly population, while minor depression 
affects another 10% (Palsson, 1997). Although 36% of men and women in 
nursing homes take antidepressants, it is estimated that 60% of the elderly 
population with MDD are untreated (Steffens, 2000; American Society of 
Consultant Pharmacists, 2002). Suicide rates are especially high in the 
elderly population compared to younger individuals with MDD. For 
example, in a Finnish study, all suicides that occurred over the span of a 
year were investigated (Henriksson, 1995). By retrospectively looking 
through patient files, the study revealed that 91% of suicide victims had at 
least one Axis I DSM-IV disorder; and in 67% it was a depressive disorder. 
Furthermore, almost all the elderly female victims had MDD.  
Lastly, epidemiologic studies of adults have reported increasing lifetime 
prevalence rates of depression in those born later in the 20th century; 
however, other studies blame this on recall bias, as it may be harder and 
harder to remember earlier life events for the older age groups (Kessler, 
1994). 
 
 
 
1.2  Theories of Major Depressive Disorder 
1.2.1 Historic Approaches 
1.2.1.1 Overview 
Since the earliest civilisations, explanations of depression have ranged 
from work of the gods, imbalanced humours, faulty nerves, and recently 
neurological and genetic explanations. However, from the very beginning, 
non-biomedical factors such as the loss of a loved one or loss of an 
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occupation have never been ruled out as causal factors (Conrad, 1995), 
implying a diathesis – stress model for depression. 
 
1.2.1.2 From Antiquity to the 19th Century  
The earliest mention of depression is for the most part religiously 
oriented. The Old Testament contains references to depression in the Psalms 
of David (Davison, 2006). Writings pertaining to depression are also seen on 
preserved portions of Egyptian papyri and in the Indian Ramayana and 
Mahabharata. 
The Greeks, specifically Hippocrates, were the first to presume that all 
bodily processes, health, and disease (including melancholia) were 
independent of supernatural phenomena (Conrad, 1995). It was thought that 
an excess of black bile in the brain caused melancholia, which literally 
translates to ‘black bile’ in Greek. Hippocrates described his depressed 
patients' symptoms as including "aversion to food, despondency, 
sleeplessness, irritability and restlessness" (Davison, 2006). Treatment 
included alterations in one's diet, as well as physical exercise routines.  
During the Medieval Ages, it was thought that melancholy could be 
caused by changes in the atmosphere that would influence levels of internal 
bile. In extreme cases of depression the moon was to blame, leading to the 
origin of the word "lunacy" or "lunatic." Excess "passion" and the influence 
of the devil were also easy explanations. 
The enlightenment brought one-on-one interpersonal therapy as 
treatment, utilizing kindness, reason, and humanity (Conrad, 1995). This 
approach was initially hard to practice, as the location of treatment occurred 
in isolated lunatic asylums where treatment was anything but humane. 
 
1.2.1.3 Psychoanalysis 
In the 1890s, Sigmund Freud fathered psychoanalysis. For Dr. Freud, 
depression was the product of past, often remote, life events that affected the 
current life of a patient (Davison, 2006). "Guilt ridden anger," caused by 
these repressed memories, turned inward to cause depressive symptoms. To 
treat depression, psychoanalysts have three main objectives: first, to 
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investigate the patient's mind and find out how he or she thinks; second, to 
establish a systemized set of theories about the patient's behaviour; and 
third, to develop a method of treatment for the depression (Moore, 1968). In 
the year 2000, there were over 35 psychoanalytic training institutes in the 
United States alone accredited by the American Psychoanalytic Association 
(aspa.org). 
 
1.2.2 Contemporary Approaches 
1.2.2.1 Behaviourism 
Just after the introduction of psychoanalysis, a new body of thought 
emerged with another explanation of depression. The behaviourist school of 
thought only deals with observable and measureable behaviour (Nemade, 
2007). American psychologist John Watson eschewed the idea that 
behaviour has anything to do with unconscious or repressed memories, 
stating instead that human behaviour is always learned. Behaviourists 
reasoned that because depression is learned, it could be unlearned (Nemade, 
2007). In the 1970s Peter Lewinsoln introduced a learning theory to explain 
depression. His theory was composed of two variables: life stressors and 
lack of personal skills. He stated that in the presence of life stressors people 
receive less positive reinforcement; positive reinforcement occurs after 
people do rewarding and pleasurable activities (Nemade, 2007). According 
to behaviourist thought, when people do not receive positive reinforcement 
after experiencing pleasurable activities they will not learn to repeat them. 
Lewinsoln suggested that a depressed individual is one who does not know 
how to act in order to start receiving positive reinforcement, due to poor 
personal skills. A specific example of this theory could be observed when a 
child changes schools and loses old friends. If the child lacks personal skills 
to replace his or her friends, no new friends will be made and the child will 
receive less positive reinforcement and will become depressed (Nemade, 
2007).  
 
1.2.2.2 Biochemical Theories 
Grant 17 
	  
Specific alterations in neurotransmitters, hormones, and growth factors 
are seemingly related with the aetiology of depression. Abnormalities in the 
most abundant inhibitory and excitatory neurotransmitters, Gamma-
Aminobutyric Acid ‬ (GABA) and Glutamate respectively, are witnessed in 
the depressed brain (Hasler, 2007; Drevets, 2008). Serotonin, a 
neurotransmitter associated with the feeling of happiness, as well as 
serotonin receptors are seen to be abnormal (Ayd, 1956; Caspi, 2003; 
Drevets, 2008; Haddjeri, 1998; Lopez, 1998; Neumeister, 2002). 
Furthermore, increased levels of the stress hormone Cortisol is detrimental 
to brain function and has been linked to MDD (Drevets 2008; Gold, 2002). 
Finally, low levels of neurotrophic growth factors are witnessed in 
depression and cause decreased neurogenesis (Banasr, 2006; Chen, 2006; 
Musselman, 1993; Oomen, 2007; Schmidt, 2007; Wong and Herbert, 2004). 
 
1.2.2.2.1 Glutamatergic and GABA-ergic Systems 
Research performed within the last ten years has shown concentrations 
of GABA to be abnormally low in both the plasma and cerebrospinal fluid 
of MDD patients (Hasler, 2007). Cortical concentrations of GABA and 
glutamate can be measured using magnetic resonance spectroscopic 
methods. These studies have shown deficits in glutamate and GABA 
concentrations in the occipital cortex of depressed patients (Drevets, 2008).  
Abnormally reduced GABA concentrations were discovered to be localized 
in the dorsomedial anterolateral Prefrontal Cortex (PFC) as well (Hasler, 
2007). Interestingly, areas in the frontal cortex have been shown to be 
volumetrically smaller in MDD patients as well10. These studies suggest that 
a change in the ratio between inhibitory and excitatory neurotransmitters 
may contribute to the altered brain function seen in depression11. ‬ 
 
1.2.2.2.2 Serotonergic System 
Low levels of serotonin were speculatively linked to the development of 
MDD over 50 years ago—an association that has paved the way for current 
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and more conclusive studies. The association was first realised in 1956 after 
the release of Reserpine, a drug used to treat high blood pressure. On top of 
treating hypertension, the drug also caused depression by lowering brain 
serotonin levels (Ayd, 1956). Once the association between low serotonin 
and depression was realised, new medications including tricyclic drugs and 
monoamine oxidase (MAO) inhibitors were introduced to the market to 
increase levels of serotonin in order to treat MDD. Selective Serotonin 
Reuptake Inhibitors (SSRI) are now the most common type of 
antidepressant medication prescribed. SSRIs increase the amount of 
extracellular serotonin in the brain by inhibiting neurons’ ability to reabsorb 
serotonin from the synaptic cleft. This effectively increases the amount of 
free serotonin in the synaptic cleft that can interact with presynaptic 
receptors, causing an antidepressant response. On top of increasing free 
levels of serotonin in the brain, it has been shown that SSRIs increase post-
synaptic serotonin receptor function as well (Haddjeri, 1998). A down side 
to SSRIs is the fact that antidepressant effects take weeks to be seen, 
suggesting that efficacy is based upon downstream modulations in neural 
structures and networks.  
More recent research suggests that more complex associations are 
present between the serotonergic system and MDD. As opposed to simply 
depleted levels of serotonin, intracellular cascades triggered by the 
monoamines (including serotonin) are involved in the onset of MDD (Nutt 
et al., 2006). Overall, it also seems that reduced serotonin receptor 
functioning is observed in patients with MDD. At this point it is unclear 
whether this deficit is due to neurodevelopmental or hereditary factors 
(Drevets, 2008). It has been hypothesized that the reduction in serotonin 
receptor binding occurs only after cortisol has been released in dangerously 
high levels—as serotonin receptor density is under tonic inhibition by 
glucocorticoid receptor stimulation (Lopez, 1998). This also has been 
observed in rat depression models, as increased cortisol secretion due to 
stress has decreased serotonin receptor density (Lopez, 1998). 
It seems that one’s serotonin receptor sensitivity plays a large role in the 
development of depressive symptoms; it was observed that by artificially 
lowering patients’ serotonin levels, temporary depressive symptoms were 
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seen in individuals with less sensitive serotonin receptors (Neumeister, 
2002). Altered serotonin transporter function may also contribute to the 
pathophysiology of depression. If an individual acquires homozygous short 
alleles for the serotonin transporter protein, one is more vulnerable to 
develop depression after experiencing stressful life events (Caspi, 2003). 
This seemingly shows that one has a genetic threshold to stress, determined 
by which alleles of the serotonin transporter one inherits.  
 
1.2.2.2.3 Glucocorticoid System/HPA Axis  
The HPA axis is a set of feedback pathways between the Hypothalamus, 
Pituitary Gland, and Adrenal Gland that regulate one's reaction to stress. 
When an individual is exposed to a stressful situation, the hypothalamus 
secretes Corticotrophin-Releasing Factor (CRF), which causes the anterior 
pituitary gland to release Adrenocorticotropic Hormone (ACTH). ACTH up-
regulates the production and secretion of cortisol from the adrenal gland. 
Cortisol is a steroid hormone, which allows the body to prepare for and to 
deal with stress. Overactivity of the HPA axis has been observed in MDD 
patients. Evidence of an overactive HPA axis can be seen in post mortem 
studies that show decreased CRF receptor density in the PFC of depressed 
patients, and that corticotrophic cell size is increased in depressed patients’ 
pituitary glands (Gold, 2002; Drevets 2008). In living patients, severe 
depression is associated with hypersecretion of cortisol, pituitary and 
adrenal gland enlargement, and higher-than-average levels of CRF in the 
cerebrospinal fluid—this last finding suggests that deficits exist in the 
negative feedback system of the HPA axis, as high levels of cortisol usually 
inhibit ACTH and CRF synthesis and release (Gold 2002; Drevets, 2008). 
High levels of cortisol have been shown to cause atrophy of hippocampal 
neurons, explaining why hippocampus volumes are smaller in depressed 
patients12.  
 
1.2.2.2.4 Neurogenesis and MDD 
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High levels of stress, as measured by high levels of glucocorticoid 
hormones such as cortisol, are one of the leading causes of the cessation of 
adult neurogenesis (Oomen, 2007; Wong and Herbert, 2004). High levels of 
glucocorticoids, such as cortisol, reduce expression of brain-derived 
neurotrophic factor and nerve growth factor, both of which increase 
neurogenesis (Schmidt, 2007). After successful treatment of MDD, serum 
cortisol and CRF levels normalize and neurogenesis is again noticed in adult 
hippocampal cells (Musselman, 1993; Chen, 2006; Banasr, 2006). This 
cessation in neurogenesis may have implications on altered brain 
functioning observed in MDD13, as well as reduced hippocampal volumes14. 
 
1.2.3 Neuroanatomical Approaches to Major Depressive Disorder 
1.2.3.1 Overview 
Converging studies have discovered decreased volumes in multiple 
regions of the depressed brain, as described in the following sections. 
Recent technological advancements, predominantly functional Magnetic 
Resonance Imaging (fMRI), have allowed researchers to also explore 
metabolic profiles of brain areas affected by MDD. It has been noticed that 
some areas are hyperactive compared to the healthy brain, while other areas 
are hypoactive—specific examples are further discussed in this paper15. By 
observing which areas are affected, it seems that the neural networks that 
modulate aspects of normal emotional behavior have been implicated in the 
pathophysiology of MDD (Drevets, 2008). These affected brain areas are 
now being targeted with invasive treatment options16, and their respective 
metabolic profiles can be used as markers to track whether treatment has 
been effective, using fMRI (Mayberg, 2009). When effective, medication, 
psychotherapy, Electroconvulsive Therapy, Vagus Nerve Stimulation, 
ablative surgery, and Deep Brain Stimulation have shown convergent fMRI 
findings in normalization of frontal brain abnormalities (Mayberg, 2009; 
Fitzgerald, 2008; Kennedy, 2001; Pardo, 2008; Nobler, 2001).  
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Grant 21 
	  
It seems that depression is not caused by dysfunction in one specific 
brain region, but rather it is thought to be a system wide disorder affecting 
brain regions involved in emotional control (Mayberg, 1997). More 
specifically, the "dorsal network" associated with emotional regulation 
(consisting of the dorsal prefrontal cortex regions) and the "ventral network" 
involved in emotional experience (consisting of the hippocampus, 
amygdala, ventral ACC, OFC, and basal ganglia—predominantly the 
striatum17) are disrupted in individuals with depression (Davidson, 2002). 
Usually changes in the structural architecture of the brain are only observed 
in adult patients with a longer or more severe clinical history (Pattern, 
2006). The ability to observe affected brain structures allows us to further 
understand the neuropsychology of MDD and to discover potential targets 
for invasive treatment options18.  
It is important to note that side effects of medications could be a very 
real confounder in studies looking at volumetric changes in the depressed 
brain. The studies included in this thesis were not controlled for the use of 
identical medications among subjects, and some subjects are medicated 
while others are not. Specific examples of this issue are addressed later in 
this thesis19. 
 
1.2.3.2 Neural Structures Implicated 
Below, volume and activational abnormalities in the MDD brain are 
discussed. In general, prefrontal areas show decreased activity on fMRI—in 
the dorsomedial and dorsolateral prefrontal cortices specifically (Phillips, 
2003). Limbic regions, important for the recognition and experience of 
emotion, are overactive in depressed patients—specifically in areas such as 
the subgenual cingulate cortex, amygdala, insula, ventrolateral prefrontal 
cortex, ventral striatum, and the thalamus (Phillips, 2003). These affected 
neural structures have a direct impact on the functional abilities of the brain 
in actively depressed patients. 
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1.2.3.2.1 Temporal Lobes 
In a meta-analysis, Lorenzetti et al. (2009) looked at all relevant articles 
published after the year 2000 pertaining to structural brain abnormalities in 
MDD. It was found that in studies looking at total temporal lobe volume, no 
differences could be determined between MDD patients and healthy controls 
(Lorenzetti, 2009). However, differences could be seen when certain regions 
of interest were isolated from within the temporal lobe. For example, 
Vythilingam et al. (2004) found evidence that in MDD patients, the left 
temporal lobe was smaller compared to the right. Studies looking at 
particular areas of the temporal lobe such as the Superior Temporal Gyrus 
(STG) have shown mixed results. Smaller volumes of the STG have been 
observed by Shah et al. (2002). The evidence to date provides no proof for 
differences in the volume of the temporal lobe due to sex, effects of 
medication, or family history (Lorenzetti, 2009). 
 
1.2.3.2.2 Hippocampus 
The hippocampus is the most studied area affected by MDD. Smaller 
hippocampal volumes are associated with patients who have had multiple 
depressive episodes as opposed to those experiencing their first episode 
(Caetano, 2004). The results of multiple studies converge in their findings 
and state that volume loss in the hippocampus can be observed due to MDD 
(Bremner, 2000; Caetano, 2004; Frodl, 2002, 2004, 2006; Lange and Irle, 
2004; MacQueen, 2003; Neumeister, 2005; Saylam, 2006; Shah, 2002; 
Sheline, 2003; Weniger, 2006). Other studies have found no difference 
between hippocampal volumes in MDD patients compared to healthy 
controls (Hastings, 2004; Monkul, 2007; Morys, 2003; Posner, 2003; Rusch, 
2001; Vythilingam, 2002, 2004). Protocol issues, and differing patient 
genders and ages used in the studies are likely to blame for these 
differences. 
Interestingly, gender may influence the relationship between 
hippocampal volume and illness duration (Lorenzetti, 2009). After a female 
experiences her first depressive episode, it has been observed that 
hippocampal volumes actually increase, while in males under the same 
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conditions hippocampus volume decreases (Frodl, 2002). This could suggest 
that the pathophysiology of MDD may affect the hippocampus in males 
differently than it does in females. These differences may explain why more 
females become depressed than males. 
Medication effects complicate results as well, not only because certain 
medications affect hippocampal volume, but also because they affect males 
and females differently. For example, females that responded to 
antidepressants have been shown to have larger hippocampal volume 
compared to female non-responders, while in males this was not the case 
(Vythilingham, 2004). This may suggest that antidepressants affect males 
and females differently, or that there are different neurological mechanisms 
of MDD at work in males and females. Medication-free patients have been 
shown to have smaller hippocampal volumes than patients on medication 
(Saylam, 2006).   
 
1.2.3.2.3 Amygdala 
The amygdala is no exception to the idea that structural changes are 
associated with longer MDD duration. It seems that the size of the amygdala 
is dynamic throughout the course of MDD (Lorenzetti, 2009). Interestingly, 
patients who are experiencing their first depressive episode show increased 
amygdala volume (Frodl, 2002, 2003; Lange and Irle, 2004;Weniger, 2006). 
Studies looking at MDD patients with more severe symptoms, as well as 
longer illness duration, found that the amygdala is volumetrically smaller 
(Bremner, 2000; Caetano, 2004; Hastings, 2004; Monkul, 2007). Post 
mortem studies also show reduced glial cell density in the amygdalas of 
reported depressed individuals (Bowley, 2002). 
Gender also appears to play a role in how MDD affects the amygdala. 
Smaller amygdala volumes have been reported in females, but not in males 
(Hastings, 2004). Research thus far has shown no relationship between 
medication or family history on amygdala volume (Lorenzetti, 2009). 
 
1.2.3.2.4 Frontal Lobes 
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The main area studied in the frontal lobe pertaining to MDD is the 
orbital frontal cortex (OFC). In patients with a history of multiple depressive 
episodes and severe symptoms, decreases in OFC volume have been 
observed; this volume reduction is not seen in patients with less severe 
depression (Bremner, 2002; Frodl, 2006; Monkul, 2007; Shah, 2002). OFC 
lesions are associated with negative emotionality (Salloway, 2001). On the 
other hand, euphoria, exuberance, and hyperactivity are sometimes seen 
when the OFC has reduced functioning. Speculatively, this would imply that 
in the case of MDD, a reduction in volume as opposed to reduced 
functioning of the OFC could be contributing to clinical symptoms. Post 
mortem studies show reduced glial cell density in the orbitofrontal cortex 
(Drevets, 1998). Lacerda et al. (2004) noted that reduction in volume was 
seen in only male participants.  
Interestingly, studies of post stroke brain functioning also shed insight 
into this discussion. It has been observed that after left sided lesions to the 
frontal cortex (including the basal ganglia20) depressive symptoms are 
common. Right-sided lesions, on the other hand, can produce euphoria or 
indifference (Salloway, 2001). All investigators do not agree upon these 
findings.  
Differences in brain metabolism have also been observed in the frontal 
lobes. Reductions in brain activity have been detected in the dorsomedial 
and dorsolateral prefrontal cortices (Soares, 1997), while increases in brain 
activity have been noted in ventrolateral prefrontal cortex (Drevets, 1992). 
 
1.2.3.2.5 Anterior Cingulate Cortex 
The Anterior Cingulate Cortex (ACC) is activated when emotional 
regulation is required in situations where behaviour is failing to achieve a 
desired outcome (Ochsner, 2001). A characteristic symptom of depression is 
the lack of a "will-to-change," possibly arising from a dysfunctional ACC 
(Davidson, 2002). 
The ACC comprises two distinct regions unique in their neural 
connectivity and cytoarchitectural features (Yucel, 2008). The Subgenual 
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Prefrontal Cortex (SGPFC) and subcollosal gyrus form the rostral-ventral 
subdivision of the ACC, an area thought to be associated with the regulation 
and assessment of emotional responses (Bush, 2000). This rostral-ventral 
subdivision has connection to other areas that are affected by MDD, 
including the amygdala, anterior insula, hypothalamus, nucleus accumbens, 
and the orbitofrontal cortex (Yucel, 2008). The dorsal part of the ACC, 
including the paracingulate gyrus, is more involved in cognitively 
demanding information, bordering the prefrontal and parietal cortices 
(Yucel, 2003). Both of these subdivisions have their own metabolic profile 
and are differentially affected in MDD (Ressler, 2007), with hyper-
activation of the Subgenual Cingulate Gyrus (SCG) and hypo-activation of 
the anterior cingulate cortex (Mayberg, 2005).  
Patients who have experienced three or more depressive episodes have 
been found to have smaller subcallosal gyrus volumes, while patients with 
three or fewer episodes have similar subcallosal gyrus volumes to healthy 
controls (Yucel, 2008). This again follows the idea that MDD symptoms 
take time to affect brain structures. It is of particular interest that the 
subcallosal gyrus forms part of the negative-feedback system of the HPA 
axis (Diorio, 1993) 21. Post mortem studies show reduced glial cell density in 
the ACC (Drevets, 1997). No differences were determined in SGPFC or 
paracingulate gyrus volumes between depressed patients and healthy 
controls (Yucel, 2008). When the ACC is looked at as one structure it has 
been found that the left ACC is smaller in MDD patients (Caetano, 2006).  
 
1.2.3.2.6 Basal Ganglia 
The basal ganglia is one of the least studied brain areas associated with 
MDD, with only three articles meeting criteria for a 2009 meta-analysis 
performed by Lorenzetti et al. Certain studies have found that basal ganglia 
volume decreases in MDD patients compared to healthy controls (Shah, 
2002). Among the specific areas involved in the basal ganglia (striatum, 
globus pallidus, substantia nigra and subthalamic nucleus), it seems that the 
striatum is the most reduced in volume. Other studies looking at the basal 
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ganglia have found no difference in volumes between individuals with and 
without MDD (Bremner, 2000). Research thus far has not looked into 
effects related to gender or medication effects (Lorenzetti, 2009). 
 
 
1.3  Neurosurgery for Mental Disorders (NMD) 
1.3.1 Overview 
Although current antidepressant medication and psychotherapy are 
viable treatment options for some patients with MDD, only 50% to 60% of 
individuals respond to any one medication and only 35% become symptom 
free (Kupfer, 2003). Relapse of depressive symptoms is the norm in the 
majority of depressed patients (Warden, 2007). Approximately 20% of those 
who have depression are resistant to medications and psychotherapy 
(Malone, 2010). Many antidepressants have undesired side effects—
impotence and other sexual problems, headache, and nausea, to name a brief 
few. It has been observed that the regular administration of psychotherapy is 
only effective in treating certain subtypes of depression (Frank, 2002). It is 
because of findings such as these that neurosurgery to treat mental disorders 
has been considered an experimental treatment option. In some cases, the 
neurosurgeries discussed below are giving treatment resistant patients a 
new, depression-free outlook on life. 
 
1.3.2 The Early Days of NMD (1930-1950s) 
In 1935, Antonio Caetano de Abreu Freire Egas Moniz won the Nobel 
Prize for discovering the therapeutic value of the leucotomy in certain 
psychoses (Nobelprize.org). The procedure disrupted connections to and 
from the prefrontal cortex, initially performed by drilling holes in a patient’s 
head and injecting an alcoholic solution. Walter Freeman and James Watts, 
a neuro-psychiatrist and neurosurgeon respectively, developed a new 
method in 1945 called the trans-orbital lobotomy. Incidence rates of the 
lobotomy soon decreased as unwanted side effects were observed—
including personality changes. 40,000 lobotomies were performed in the 
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USA, 17,000 in the UK, and 9,300 in Scandinavia (Tranoy, 2005). The 
quality of published research during this time was very poor, and in some 
instances data were not collected at all. Understandably, public concern 
developed in countries where side effects could be observed. 
  
1.3.3 The Renaissance of NMD 
1.3.3.1 Overview 
In 1977, a US presidential commission was drafted to respond to public 
concern pertaining to psychosurgery and addressed adverse side effects. The 
report concluded that psychosurgery should be continued, but more stringent 
patient consent, surgeon competency, and data monitoring pre and post 
surgery outcomes should be pursued (Dhew Publication No. (OS) 77-0001, 
1977). 
 NMD is experiencing a renaissance because of the data from MRI and 
post-mortem studies indicating specific affected brain areas that serve as 
targets for intervention. The theory behind today’s neurosurgical techniques 
is based upon targeting the dysfunctional emotional and cognitive brain 
areas discussed above. Very localized lesions are created to minimize side 
effects. Specific brain areas can be located very precisely using imaging 
techniques, and in certain procedures no brain tissue needs to be destroyed. 
Many procedures are reversible, such as Deep Brain Stimulation and Vagus 
Nerve Stimulation, and many can be modulated even after surgery via 
external devices (Jamie, 2007).  
In the following sections pertaining to surgical treatments of depression, 
the quality of the research is taken into account to better judge how 
trustworthy certain studies are. To do this the Eigenfactor (EF) and Article 
Influence (AI) Scores are used, both of which scale the total impact of a 
journal. Each test has a possible 100 as a maximum score 
(http://www.eigenfactor.org). 
 
1.3.3.2 Vagus Nerve Stimulation 
Vagus Nerve Stimulation (VNS) was initially used to treat medication 
resistant epilepsy. In fact, over 17,000 individuals worldwide have had a 
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VNS implanted to help treat their epilepsy (Elger, 2000). Interestingly, it 
was observed that not only were these patients having fewer seizures, but 
also their general mood improved independently of having fewer seizures 
(Harden, 2000). These findings began an exploration using VNS to treat 
TRD. On July 15th, 2005 VNS was approved by the US Food and Drug 
Administration (FDA) for "adjunctive long-term treatment of chronic or 
recurrent depression for patients 18 years of age or older who are 
experiencing a major depressive episode and have not had an adequate 
response to 4 or more adequate antidepressant treatments" (Nahas, 2006). 
The known neuroanatomy of the vagus nerve played a large part in the 
argument of using VNS to treat TRD. The vagus nerve controls the 
cardiovascular, respiratory, and gastrointestinal systems (Nahas, 2006). 80% 
of the vagus nerve fibers are afferent and carry information to the brain 
(Foley, 1937). The vagus nerve enters the brain in the midbrain at the 
Nucleus Tractus Solitaris (NTS) (Nahas, 2006). From here, fibres create a 
classic reflex arc and either connect to the reticular activating system or 
reach the parabrachial nucleus and its connections to other brain areas—the 
raphe nucleus, thalamus, paralimbic, limbic and cortical regions including 
the anterior insula and cingulate cortex (Bachman, 1977; Nahas, 2006). 
Many of these brain areas are involved in the neuroanatomy of depression; 
of specific note are the cingulate cortex, limbic areas including the 
amygdala and hippocampus, and the raphe nucleus (where serotonin is 
synthesized).  
An imaging study using Positron Emission Tomography (PET) also 
played a role in justifying the use of VNS to treat TRD—the study showed 
increased cerebral blood flow to the rostral and dorsal-central medulla, right 
postcentral gyrus, hypothalami, thalami, insular cortices, and in cerebellar 
hemispheres after VNS surgery (Henry, 1998). Blood flow was decreased in 
hippocampus, amygdala, and posterior cingulate gyri following VNS 
surgery (Henry, 1998). These areas overlap with the neuroanatomy of MDD. 
Another study shows similar results, indicating that cerebral blood flow is 
increased in the dorsolateral prefrontal cortex after VNS in TRD patients 
(Kosel, 2010).  
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It is important to note that during VNS it is due to both orthodromic and 
antidromic stimulation of the Vagus Nerve that leads to aforementioned 
changes in neural blood flow (Henry, 1998). Orthodromic activation occurs 
at afferent axonal terminals in the brainstem, while antidromic activation 
occurs through efferent axons that project from the brainstem to the 
peripheral autonomic ganglia. It is impossible to determine which medullary 
nuclei generated the blood flow increases observed during VNS due to 
limitations of spatial resolution of the PET scanner (Henry, 1998). 
To perform a VNS, a neurosurgeon implants a pacemaker-like generator 
in the anterior chest wall (Nahas, 2006). Leads coming off the pacemaker 
are wrapped around the cervical portion of the left vagus nerve (Nahas, 
2006). The intensity, duration, pulse width, and duty cycle of electricity 
delivered to the nerve can be varied using an external device. After three 
months of active VNS it has been observed that the major metabolites of 
dopamine and serotonin are increased in cerebral spinal fluid (Ben-
Menachem, 1995). 
Previous studies have shown success in VNS procedures. Patients were 
considered responders if their depressive symptoms decreased by 50% as 
measured by the HRSD-1722 questionnaire; patients were in remission if 
they scored a seven or less on the HRSD-17 (Eljamel, 2008). In a study 
published by Nahas et al. 2005 in the Journal of Clinical Psychiatry (EF: 
95, AI: 91) consisting of 60 patients, 30.5% showed a clinical response after 
only 8 weeks post VNS surgery. At the 12-month mark post-surgery, 
remission rates increased to 44.1%, and at 24 months post-surgery remission 
rates were 42.4% (Nahas, 2005). Quality of life self-assessment tests 
showed that quality of life improved by 47% 12 months post-surgery and 
56% 24 months post-surgery (Nahas, 2005). Another study published in the 
British Journal of Psychiatry (EF: 95, AI: 95) including 11 patients showed 
a 55% clinical response rate and a 27% remission rate post one year of 
surgery (Corcoran, 2006). It is interesting to note that like antidepressants, 
there is a lag between initiation of treatment and clinical improvement in 
symptoms. Whether these time lags are the same between the two different 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
22 Hamilton Rating Scale for Depression is a multiple choice questionnaire that rates the severity of a 
patients depression 
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treatments is difficult to measure based on the limited number of VNS 
studies relating to MDD, as well as the fact that remission rates are 
measured at set intervals. If remission rates were continuously monitored 
for, a more precise remission time frame could be determined and could be 
compared to the treatment delay expected of antidepressant therapy. 
Side effects are associated with VNS; however they are usually less 
severe than those associated with the anterior cingulotomy and capsulotomy 
as no brain matter is destroyed. 1.1% of individuals with a VNS device 
installed experience hoarseness and temporary vocal cord paralysis if the 
laryngeal nerve is damaged during surgery (Nahas, 2006). During surgery, 
0.1% of patients showed a flatlined electrocardiogram, but were resuscitated 
with no long-term consequences (Nahas, 2006). 
 
1.3.3.3 Anterior Cingulotomy (ACING) 
The anterior cingulotomy is another treatment option for those who have 
TRD. Although the procedure has been practiced in the United States and 
Great Britain for many years, an exact lesion location and lesion volume are 
still not agreed upon and will vary in accordance with an individual’s unique 
anatomy. Procedures using standard stereotactic neurosurgical procedures 
(Steele, 2008) also differ between centres. 
The surgical technique is as follows. MRI is used to determine the lesion 
site to 1mm accuracy. These coordinates are located in the patient’s brain to 
a 1mm accuracy using a stereotactic frame. The bilateral targets are points 
1mm above the roof of the lateral ventricle, 7mm lateral to the midline, and 
20mm posterior to the tip of the frontal horn (Steele, 2008). A skin flap is 
cut and a bur hole created. Through the hole an exposed electrode is inserted 
into the correct coordinate and heated to 70°C for 90 seconds, repeated 
twice. The procedure is performed bilaterally. 
The lesion affects the cingulum bundle and the cingulate cortex. The 
cingulum bundle has extensive connections to other regions in the cingulate 
gyrus, the hippocampus, prefrontal cortex, and the amygdala—all areas 
where deficits are seen in MDD patients (Steele, 2008; Shields, 2008). The 
positive effects of the surgery are often seen months after surgery, hinting 
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that downstream effects, such as rewiring of white matter tracts, are to 
blame for clinical effectiveness (Shields, 2008). 
Lesion volume and location on the cingulate are important variables. It 
has been observed that more anterior lesions are more effective than 
posterior lesions, and interestingly that smaller lesions prove to be more 
effective than larger lesions (Steele, 2008). This is interesting because many 
centres, such as Massachusetts General Hospital, routinely perform a second 
cingulotomy if the first is unsuccessful at acquiring remission. It seems that 
it is in fact the location of the surgery that is more important; more 
specifically, the more rostral the lesion the more effective it seems to be 
(Steele, 2008). 
In the few studies conducted so far, very positive results have been 
achieved. In a study conducted at Ninewells Hospital in Dundee, Scotland, 
eight patients were given an anterior cingulotomy. Patients were considered 
responders if their depressive symptoms decreased by 50% as measured by 
the HRSD-17 questionnaire; patients were in remission if they scored a 
seven or less on the HRSD-17 (Eljamel, 2008). After 12 months post 
surgery, 25% responded to surgery with less depressive symptoms and 
37.5% reached remission (Steele, 2008). Steele et al. 2008 published their 
findings in Biological Psychiatry (EF: 99, AI: 98). 
Significant improvements were observed on the Paired Associated 
Learning and Spatial Learning Memory tasks 12 months after surgery. This 
shows a greater planning ability, possibly due to alleviation of depressive 
symptoms. A Harvard Medical School study consisted of 17 anterior 
cingulotomy patients. At a long term follow up, 41.2 % were classified as 
responders, 35.3% were partial responders, and 23.5% did not respond 
(Shields, 2008). Shields et al. 2008 published their findings in Biological 
Psychiatry (EF: 99, AI: 98). In a third study of five patients published in 
Neurosurgical Focus (EF: 85, AI: 95), after 12 months, 60% of patients 
were responders, and 20% achieved remission (Eljamel, 2008). In all 
patients who undergo a cingulotomy, hypermetabolism in the subgenual 
cingulate cortex and prefrontal cortex can predict surgical response 
(Dougherty, 2003). 
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Although there are clear clinical benefits related to anterior 
cingulotomies, side effects do exist. Headache, nausea, dizziness, 
incontinence, involuntary limb movements, trouble pronouncing words, and 
facial swelling can occur (Eljamel, 2008; Shields, 2008). Serious side effects 
have included the development of epilepsy in one patient and serious mental 
incapacitation in another (Eljamel, 2008; Shields, 2008). 
 
1.3.3.4 Anterior Capsulotomy 
The anterior capsulotomy is another example of a stereotactic brain 
surgery used to treat TRD. The procedure was first used in 1949 by Dr. 
Talairach and his colleagues to treat chronic pain (Eljamel, 2009). During 
the procedure, the most anterior portion of the anterior limb of the internal 
capsule lateral to the head of the caudate nucleus was lesioned. The removed 
area connects the frontal and anterior cingulate cortex with the thalamus, 
hippocampus, and amygdala (Eljamel, 2008). 
Preparation of the patient and planning of the procedure are exactly the 
same as the steps used in an Anterior Cingulotomy; MR images are taken to 
find lesion coordinates and a stereotactic frame is used to precisely locate 
the mentioned coordinates (Eljamel, 2008). During the operation, an 
exposed electrode is heated to 70°C twice on both the left and right side, 
meaning that the lesion is twice as big compared to the anterior 
cingulotomy. Positive results are often seen months after surgery in the 
same manner observed in the anterior cingulotomy. 
One study conducted in Ninewells Hospital included 20 bilateral anterior 
capsulotomy patients. 12 months post-surgery, 25% of patients were 
responders and 10% were in remission. Long-term remission rates were 
40%. Despite good remission rates after surgery, side effects are associated 
with anterior capsulotomy. These include headache, nausea, dizziness, 
incontinence, involuntary limb movements, trouble pronouncing words, and 
facial swelling (Eljamel, 2008; Shields, 2008). In one patient, intracerebral 
haemorrhage occurred during surgery and led to permanent hemiparesis 
(Eljamel, 2008). Shields et al. 2008 published their findings in Biological 
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Psychiatry (EF: 99, AI: 98), Eljamel published in Neurosurgical Focus (EF: 
85, AI: 95). 
 
1.3.3.5 Deep Brain Stimulation 
1.3.3.5.1 Overview 
Deep Brain Stimulation (DBS) has been introduced over the last decade 
and represents the most recent class of invasive procedures used to treat 
TRD MDD patients. The surgery is stereotactic and non-ablative, therefore 
removal of the implanted electrodes is almost completely reversible. 
Researchers also have the ability to vary stimulation sites and parameters in 
any individual patient to maximize clinical outcome (Malone, 2010). An 
abundance of research is underway utilizing DBS technology to study 
treatment options not only for TRD, but also refractory Obsessive-
Compulsive Disorder (OCD) and Tourette syndrome. In fact, recently the 
use of DBS has been approved by the FDA to treat OCD. 
During the surgery, MR images are taken and the patient's head is fixed 
to a stereotactic frame. Using the desired coordinates, the target brain area is 
located. Electrodes are inserted through burr holes. The electrodes are 
connected to a pulse generator inserted under the shoulder blade (Mayberg, 
2005). One week after surgery, the electrodes are turned on using the lowest 
possible voltage. Every week after their surgery the patients must return to 
have voltage levels adjusted, usually being turned up gradually for the first 
six months (Mayberg, 2005). 
Many brain areas have been targeted for implantation of a DBS device 
due to their involvement in emotional and cortical brain areas affected by 
MDD. Brain areas already targeted are the subgenual cingulate gyrus, the 
ventral striatum/ventral caudate, and the nucleus accumbens. It seems that 
the efficacy of DBS to treat refractory MDD depends on the brain area 
targeted23 Side effects are usually minimal, with infection at the electrode 
implantation site being the most common, followed by skin erosion over the 
battery pack inserted under the shoulder blade. Paresthesias, anxiety, mood 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
23 see sections 1.3.3.5.2-1.3.3.5.3 
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changes, and autonomic effects are also observed but all are reversible with 
adjustment of the stimulation parameters (Malone, 2010).  
Below studies investigating the effect of DBS on specific brain 
structures are discussed. 
 
1.3.3.5.2 Subgenual Cingulate Gyrus 
The Subgenual Cingulate Gyrus (SCG) is the brain area most targeted by 
DBS. Mayberg and colleagues at Emory University in Atlanta, Georgia 
performed the first study looking into the efficacy of DBS in the SCG 
published in Neuron (EF: 100, AI: 99). Six patients took part in the study, 
and after six months, four patients showed an antidepressant response 
measured by a 50% decrease in the Hamilton Rating Scale for Depression 
(Mayberg, 2005). Two of the six patients reached remission status after 6 
months as well. Using MRI technology, it was observed that hyper-
activation of the SCG and hypo-activation of the anterior cingulate cortex 
typical of the depressed brain were both normalized after 4 months of DBS 
treatment (Mayberg, 2005).  
Lozano et al. 2008 also had promising results in another study 
comprising of 20 subjects who underwent DBS in their SCG published in 
Biological Psychiatry (EF: 99, AI: 98). After on month, 35% were 
responders and 10% were in remission. Six months after surgery, 60% were 
responders and 35% were in remission, these benefits were maintained at 
one year (Lozano, 2008). A follow up study on the same patient group by 
Kennedy et al. 2011 showed that the average response rates at 1, 2, and 3 
years after DBS implantation were 62.5%, 46.2%, and 75%, respectively. 
Holtzheimer et al 2012 performed DBS on the SCG of 10 MDD patients 
and published results in The Archives of General Psychiatry (EF: 99 AI: 99). 
The group found remission in 18% after 24 weeks, 36% after one year and 
58% after two years. Important to note is that none of the patients who 
experienced remission had a relapse of symptoms. 
 
1.3.3.5.3 Nucleus Accumbens (Ventral Caudate/Ventral 
Striatum) 
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In animal studies, electrical stimulation of the nucleus accumbens has 
led to increased exploratory behaviour and increased food intake; self-
stimulation of the nucleus accumbens is also easily taught to rats (van 
Kuyck, 2007). This comes as no surprise, as the nucleus accumbens is rich 
in dopaminergic connections and has been dubbed a ‘pleasure centre’ of the 
brain. Currently, surgeries are being performed inserting DBS into the 
nucleus accumbens of humans as well. In 2008, a pilot study was released in 
Neuropsychopharmacology (EF: 97, AI: 95) looking at three patients that 
underwent a DBS procedure in his or her nucleus accumbens (Schlaepfer, 
2008). One of the three patients achieved a 50% reduction in his or her 
depressive symptoms during weeks 6-23. Bewernick et al. 2010 performed 
DBS on the Nucleus Accumbens of 10 patients with MDD and published 
their study in Biological Psychiatry (EF: 99, AI: 98). It was found that five 
patients reached 50% reduction of the HDRS-17 after one year. 
Interestingly, decreased metabolism in the subgenual cingulate and 
prefrontal regions including the orbital prefrontal cortex was observed in 
these patients, showing down stream effects of the surgery.  
The Ventral Caudate and Ventral Striatum (VC/VS) are also becoming 
common targets for DBS treatment. In the first study performed in 2009 by 
Malone and colleagues and published in Biological Psychiatry (EF: 99, AI: 
98), 15 patients were recruited for the procedure. Electrodes were implanted 
bilaterally in the VC/VS region to follow the dorsal-ventral trajectory of the 
anterior limb of the internal capsule (Giacobbe, 2009). After one month of 
DBS treatment, 3/15 patients reached clinical response criteria. After three 
months, 8/15 reached clinical response criteria. At a 12-month follow up, 
40% of patients had reached remission (Malone, 2009). 
 
 
1.4 The Neuropsychology of Major Depressive Disorder 
1.4.1 Memory 
Episodic memory, that is, the ability to remember new events in an 
autobiographical context is affected in patients with MDD. This type of 
memory is associated with the hippocampus (Brown, 2001). As previously 
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discussed, smaller hippocampal volumes are associated with the depressed 
brain. These smaller hippocampal volumes are possibly caused by cellular 
atrophy due to elevated levels of cortisol (Cahill, 2003; Hinkelmann, 2009; 
Gomez, 2009; Egeland, 2005). In a study exploring this hypothesis, 
dexamethasone was administered to depressed patients. Dexamethasone, 
being a more potent form of cortisol, activates the negative feedback loop of 
the HPA axis, signalling less cortisol synthesis and secretion by the adrenal 
cortex. After two days of dexamethasone administration, it was observed 
that memory performance was improved. The researchers hypothesized that 
the improvements in memory could be explained by the experimentally 
reduced levels of cortisol (Bremner, 2004). 
In a related study, researchers administered high levels of 
hydrocortisone (cortisol) to both patients with MDD and healthy subjects. It 
was discovered that after hydrocortisone administration, healthy subjects 
scored lower on declarative memory tasks, as well as general memory 
retrieval, while depressed patients scored the same as they did previously, 
again supporting the idea that high levels of glucocorticoid hormones do in 
fact affect declarative memory (Terfehr, 2010). 
Working memory is also affected in MDD. Gruber et al. (2011) looked 
at 18 patients with MDD and 18 healthy controls. It was found that eight out 
of the 18 patients performed significantly worse than the healthy controls on 
tasks involving working memory. Studies utilizing imaging technologies 
have also looked into which brain areas are irregularly active in MDD 
patients while performing working memory tasks. In a study performed by 
Matsuo et al. (2007), it was observed that the MDD brain was hyperactive in 
the left dorsolateral cortex and anterior cingulate cortex compared to healthy 
controls while performing working memory tasks. This result emphasizes 
the role of the ACC in MDD. 
Finally, a bias also exists in MDD patients towards negative memory 
formation. Depressed patients show an enhanced recall for negative 
information as compared to positive or neutral material (Murray, 1999).  
 
1.4.2 Executive Functions 
Grant 37 
	  
MDD has been associated with deficits in many subcomponents of 
executive function. Psychomotor retardation is one of the diagnostic criteria 
noted in the DSM24. In a study looking at 50 depressed patients, it was 
observed that processing speed was reduced on attention tasks (Egeland, 
2003). Mahurin et al. (2006) also suggested that processing speed and visual 
processing speed was reduced in depressed patients measured by 
performance on the Trail Making Task, a result that was replicated by Smith 
et al. (2006). Verbal fluency, combining verbal and visual cues, spontaneous 
cognitive flexibility, initiation ability and complex integration of 
information for concept formation were all impaired in a study performed by 
Fossati et al. (1999). Hill et al. (2004) pointed out that spatial abilities, 
motor skills, and attention capacity were all found to be impaired in patients 
with psychotic depression compared to healthy controls as well. 
Studies utilizing imaging technologies have also looked into which brain 
areas are irregularly active in MDD patients while performing executive 
function tasks. In a study performed by van Tol et al. (2011) utilizing MRI 
technology, performance on the Tower of London test was observed. During 
this visuospatial planning task, a patient is presented with a starting 
configuration and a target configuration and is asked to find the minimum 
number of steps needed to get from one to the other (van Tol, 2011). It was 
found that MDD patients showed increased dorsolateral prefrontal cortex 
activation while completing the Tower of London task compared to healthy 
controls. In another study, it was suggested that when depressed patients 
were performing another attention task, the Stroop test, in an MRI scanner, 
their anterior cingulate gyrus and dorsolateral prefrontal cortex were 
hyperactive compared to healthy controls (Wagner, 2006). Finally, 
depressed patients are faster to respond to sad words compared to happy 
words, a very similar finding to the bias present to form negative memories 
(Drevets, 1998). 
 
1.4.3 Emotion Processing 
1.4.3.1 Introduction 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
24 see section 1.1.2.1 
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Many neuroanatomical models exist to explain how the human brain 
recognizes emotion. These models include single-system, dual system, and 
multi-system explanations. In a meta-analysis published in 2003, 106 PET 
and fMRI studies were evaluated to find similarities in the vast body of 
research that pertains to all these explanations. In this section, the different 
system models are explored and the results of the neuro-imaging meta-
analysis are used to support or refute these models. 
 
1.4.3.2 Current Single System Emotion Recognition Models 
The first single system model exploring the neuroanatomy of emotion 
was proposed by Maclean. Included in his function-structure relationship 
was the explanation that the limbic system formed a set of neural structures 
that formed a network to decipher emotion (Maclean, 1993; Murphy, 2003). 
Another single system explanation specifically pertains to the right 
hemisphere. In humans, it has been shown that emotions are expressed more 
intensely on the left side of the face, suggesting that the right side of the 
brain, responsible for coding the left side of the face, is more active when 
coding emotions (Sackheim, 1978). In another related study, it has been 
observed that when the right hemisphere is damaged, impaired emotional 
recognition of facial expressions is noticed (Mandal, 1992; Murphy, 2003). 
When looking at the data from the meta-analysis, a relationship between 
right and left side lateralization was not observed when the brain deciphers 
emotion, nor was the posterior or anterior sections of the brain more active. 
A critical role of the right hemisphere in the encoding of emotion was not 
determined (Murphy, 2003). Many of the structures in the limbic system 
were activated across studies including the amygdala and the ACC, 
supporting MacLean’s limbic system theory (Murphy, 2003). However, 
many non-limbic areas were activated as well. 
 
1.4.3.3 Current Dual System Emotion Recognition Models 
Explanations relying on dual systems to explain emotion also exist. 
Examples of these dual explanations are positive vs. negative emotions, 
pleasant vs. unpleasant emotions, or calm vs. excited emotions. A number of 
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Electroencephalography (EEG) studies looking at animals, adults and 
children converge in their findings that positive and negative emotions rely 
on distinct neural systems (Murphy, 2003). Davidson et al. (1984) argued 
that the right hemisphere encoded positive emotions and the left hemisphere 
encoded negative ones. Building on this theory, researchers later 
hypothesized that the positive emotion coding right hemisphere was 
responsible for an approach system and the negative emotions with a 
withdrawal system (Davidson, 1999). More specifically, this approach 
system is involved in approaching positive stimuli, while the withdrawal 
system is involved in detecting punishment and inhibiting goal-oriented 
behaviour (Carver, 2004; Gray, 1981). 
The meta-analysis did not find a spatial difference between positive or 
negative emotions, as neural activity was symmetrical. However, it was 
observed that the left hemisphere was significantly more active for approach 
emotions, while no relationship was noticed for withdrawal emotions 
(Murphy, 2003). 
 
1.4.3.4 Current Multi System Emotion Recognition Models 
The final family of explanations of emotion recognition fall into 
multisystem models. In this group of explanations, emotions are stated to be 
encoded by specific neural programs called affect programs, a term first 
coined by Charles Darwin in 1872 (Darwin, 1872; Murphy, 2003). The 
definition of an affect program is a "specific neural mechanism that stores 
patterns for and triggers complex emotional responses that are quick, 
complex and organised" (Murphy, 2003). In 1982, Ekman and Friesen 
proposed fear, disgust, anger, happiness, sadness, and surprise as affect 
programs; later Ekman proved that these emotions are represented exactly 
the same cross-culturally (Ekman, 1982; Ekman 1992).  
Certain brain regions seem to be involved with specific emotional 
recognition experiences. For example, following brain lesions to the 
amygdala and surrounding areas, impairment in one’s ability to recognize 
the facial expression of fear have been observed (Adolphs et al., 1994). 
Similarly, lesions to the gustatory insula and basal ganglia have eliminated 
Grant 40 
	  
patients’ ability to recognize disgust (Calder, 2000). Regions associated with 
the recognition of happiness, sadness, or surprise have not yet been isolated 
(Murphy, 2003). 
Many interesting similarities exist pertaining to the affect program 
theory of emotion when looking at the 106 imaging studies included in the 
meta-analysis. An association between the amygdala and fear was 
determined; activity in the amygdala was observed in 40% of the studies 
dealing with the emotion of fear and in 60% of the studies looking at the 
recognition of the facial expression of fear (Murphy, 2003). These data were 
pioneered in a study by Sprengelmeyer et al. (1999), as it was discovered 
that bilateral lesions of the amygdala impaired one’s ability to process fear. 
In a second meta-analysis looking at brain activity when dealing with the 
facial expression of fear, the fusiform gyrus was also activated, as well as 
the cerebellum, left inferior parietal lobule, left inferior frontal, and right 
medial frontal gyrus (Fusar-Poli, 2008). Associations between both the 
insula and globus pallidus were established when observing the emotion of 
disgust; activity in the insula and globus pallidus was found independently 
in 70% of the studies dealing with the emotion of disgust (Murphy, 2003). 
In studies dealing with the recognition of the facial expression of disgust, 
four out of five studies showed activation in both the insula and globus 
pallidus (Murphy, 2003). The second meta-analysis also showed activation 
in the left amygdala, fusiform gyrus, bilateral temporal gyrus, and the left 
middle frontal and right inferior frontal gyri when the brain was looking at a 
facial expression of disgust (Fusar-Poli, 2008). Lateral OFC activity was 
noticed in more studies dealing with anger than in any other emotion 
(Murphy, 2003). The right cingulate and anterior cingulate gyri, the right 
parahippocampal gyrus, left cerebellum, bilateral inferior frontal gyrus and 
the right middle frontal gyrus are also consistently active when looking at 
facial expressions of anger (Fusar-Poli, 2008). When looking at sad 
emotional faces, increased activation is seen in the right occipital gyrus, left 
insula and left thalamus (Fusar-Poli, 2008). Finally, when looking at facial 
expressions of happiness, increased activation was witnessed in the left 
amygdala, left insula, left medial frontal gyrus, left putamen, left 
cerebellum, and middle temporal gyrus (Fusar-Poli, 2008). 
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It is of great importance that a general role of the Anterior Cingulate and 
Medial Prefrontal Cortices may have been found in the recognition of 
emotions. These brain areas were active in a "significant portion" of the 106 
imaging studies that were part of the meta-analysis (Murphy, 2003). Other 
studies support the idea that the frontal cortex (including the ACC) is 
important in processing general emotional cues (Damasio, 1994; Hornak, 
1996; Keane, 2002; Rolls, 1999; Murphy, 2003). Other studies have 
hypothesized that specific brain regions associated with encoding emotions 
filter into frontal brain areas such as the ACC (Sprengelmeyer, 2008). This 
hypothesis is further solidified by the fact that when these frontal brain areas 
are damaged, impairments are seen in general emotional recognition and 
experience (Keane, 2002; Murphy, 2003).  
 
1.4.3.5 Emotion Processing in Depressed Individuals 
According to the DSM-IV criteria, depression is classified as a mood 
disorder. It is no surprise that researchers have begun to explore emotion 
and facial expression processing in the depressed brain. Studies thus far 
have shown differences in how depressed patients interpret and experience 
emotions and facial expressions. Depression affects one's emotional 
experience due to specific brain structure volume reductions and abnormal 
levels of neural metabolism in a variety of brain areas associated with 
emotional processing mentioned above. 
In one of the most clear-cut studies performed thus far, the recognition 
of the facial expression of disgust was analysed in depressed patients. 68 
patients with severe depression were compared against 50 healthy 
appropriately matched controls.  It was detected that the control group was 
significantly better at recognizing the facial expression of disgust compared 
to the MDD subjects (Douglas, 2010). It was also determined that MDD 
patients were more likely to interpret neutral faces as sad and less likely to 
interpret neutral faces as happy (Douglas, 2010). In another study it was 
found that depressed patients had a negative emotional bias when 
interpreting emotion (Morris, 2009). Depressed individuals react faster to 
sad faces than any other emotion (Drevets, 1998). General emotional 
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processing deficits in MDD patients have been observed in a number of 
studies (Feinberg, 1986; Mikhailova, 1996; Persad, 1993).  
Ritchey et al. (2011) suggested that depressed patients show an 
enhanced response to negative versus positive emotional stimuli. In the 
same study, it was also detected that depressed individuals showed lower 
levels of discrimination between emotional and neutral stimuli. Selection 
bias towards negative emotional cues such as the facial expression of 
sadness, and a bias away from positive emotional cues such as happy faces 
were also mentioned by Lappanen et al. (2006). In the same article it was 
observed that individuals with major depressive disorder show increased 
neural activity in response to sad faces and decreased neural activity in 
response to happy faces. Other neuroimaging findings show that increased 
amygdala activity is detected in MDD patients when recognizing the facial 
expression of sadness (Drevets, 2001). 
A person’s ability to deal with society, their environment, and to think 
rationally was defined as ones ‘Emotional Intelligence’ by Salovey and 
Mayer et al. (1990). Personality questionnaires such as the TCI-R25 and 
SSEIT26 have been used to study ones emotional intelligence. In one such 
study, the TCI-R and SSEIT were administered to 54 inpatients with MDD 
and 54 healthy matched controls (Hansenne, 2009). Lower total Emotional 
Intelligence scores were seen in the MDD group as compared with controls. 
In the same study TCI-R and SSEIT were again administered to patients 
within the MDD group upon reaching remission from their symptoms. 
These results showed that Emotional Intelligence scores were the same in 
the MDD patients and controls. This shows that performance on emotional 
tasks can improve when a MDD patient has been treated and their symptoms 
subside. 
 
1.4.3.6 Emotion Processing in Depressed Individuals After 
Neurosurgical Procedures 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
25 The Schutte Self Report Emotional Intelligence Test (SSEIT) is a 33 item self-report measure of 
emotional intelligence 
26 The Revised Temperament and Character Inventory  (TCI-R) is an measure for personality traits 
including Novelty Seeking, Harm Avoidance, Reward Dependence and Persistence 
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Studies of emotional processing after neurosurgery in TRD patients are 
rare, and almost all literature that exists on the topic has been written within 
the last ten years. These studies are important and more are emerging as it 
has been hypothesized that impaired emotional processing may be the 
leading cause of social dysfunction among depressed patients (Surguladze, 
2004).  
One study included five patients that had received both an anterior 
cingulotomy and anterior capsulotomy and four patients that only underwent 
an anterior cingulotomy (Ridout, 2007). At the time of testing, four of the 
nine patients had reached remission and were considered non-depressed, 
neurosurgically treated patients known as responders. Two control groups 
were also included in the study for comparison: one group of 17 individuals 
currently experiencing a depressive episode and 22 healthy individuals. The 
stimuli presented to the participants were 28 video clips showing emotional 
facial expressions, body language, and emotional voices. Executive 
functions were also tested using the Stroop task, the Hayling sentence 
completion task, and the F-A-S verbal fluency task. After analysing the data, 
differences were detected among the groups. NMD patients showed 
inhibited emotional recognition compared to healthy controls. These 
differences could be explained due to the fact that without a functioning 
ACC, emotion recognition is impeded due to deficits in attention (Ridout, 
2007). The non-responders produced fewer words on the verbal fluency 
task, made more errors on the sentence completion task, and made more 
errors on the Stroop task than did the responders or healthy controls. This 
possibly shows that the responders showed measureable improvements not 
only in their mood but also in emotional recognition. Patients from the 
depressed control group produced more words on the sentence completion 
task and fewer errors on the Stroop task than did the non-responders. This 
may suggest that the neurosurgery was in fact detrimental to emotional 
processing due to deficits in attention. The ACING procedure itself has been 
seen to lead to impaired attention processing (Ridout, 2007; Cohen, 1999). 
Patients, who received an anterior cingulotomy alone, without the anterior 
capsulotomy, identified 5% more emotional cues than did patients who 
underwent both surgeries (Ridout, 2007). 
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In another study, only one patient was included who underwent an 
anterior cingulotomy (Wang, 2002). This patient showed specific deficits in 
the recognition of fear and disgust; however, this patient also had damage to 
the amygdala, and this could have affected the findings (Ridout, 2007; 
Wang, 2002). Nonetheless, volume changes are expected in the amygdala of 
the MDD brain regardless. In a study looking at patients with lesions to the 
anterior cingulate cortex, patients’ ability to recognize primary emotions 
was jeopardized (Hornak, 2003). This data supports other studies that state 
the role of the ACC in successful emotional recognition (Blair, 1999; 
Killgore, 2004). 
 
 
1.5  Research Questions 
This thesis is structured as a two-part analysis. Part One explores the 
effect of MDD on emotional processing capabilities. To do this, tasks 
assessing emotional processing27 were administered to a group of patients 
with MDD and to a control group with no history of MDD28. With the 
scores from these tests, independent group T tests were used to address the 
following questions:  
• Does MDD have an effect on emotional processing capabilities? 
• If MDD does have an effect on emotional processing capabilities, 
is emotional processing ability generally decreased/increased, or is 
performance affected in regards to a specific emotion? 
• If MDD does have an effect on emotional processing capabilities, 
are the same emotions consistently affected across different tests? 
• Are the results/outcomes consistent with other studies? 
• What can this tell us about possible neural structures associated 
with MDD? 
Part two explores the side effects of ACING and VNS to treat 
depression, as measured by scores on emotional processing tasks. To 
achieve this, two groups are analyzed: one that underwent an ACING and 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
27 see section 2.2.2 
28 see section 2.2.1	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one that underwent a VNS. Tasks assessing emotional processing were 
administered to each group before and one year after surgery. Side effects 
were compared and measured by scores before and after surgery. With the 
scores from these tests, independent group T tests were performed and 
significant increases/decreases in ability to recognize emotion were 
expressed as changes from baseline. The following questions were explored:  
• Did the invasive treatment option (ACING/VNS) affect patient’s 
emotional processing capabilities? 
• If the invasive treatment option (ACING/VNS) affected patient’s 
emotional processing capabilities, is the emotional processing ability 
generally decreased/increased or is performance affected in regards to a 
specific emotion? 
• If the invasive treatment option (ACING/VNS) affected patients’ 
emotional processing capabilities, are the same emotions consistently 
affected across different tests? 
• Can this information help us determine which neural structures are 
affected by ACING and VNS? 
• What can this tell us about possible neural structures associated 
with MDD? 
 
 
 
 
2 Study 
2.1  Introduction 
All testing was conducted in accordance with the Declaration of 
Helsinki — 2008, and required ethical approvals were obtained from the 
relevant NHS research ethics committees. Study participants provided 
written consent.  
Sprengelmeyer et al. (2011) used similar participants in their study as 
are used in this one, in that: “ [this study] not only tested participants who 
were not only taking prescribed antidepressant medication, but who had 
histories of exposure to a range of psychotropic medications. We therefore 
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cannot exclude an effect of previous or current medication to either the 
behavioural or structural findings in the MDD participants. Similarly, 
although the MDD participants were clinically representative of specialist 
and psychiatric practice in the UK and presented with a robust primary 
diagnosis, we did not exclude common co-morbidities such as anxiety and 
personality disorders” (p.121). The fifteen MDD participants in Part One are 
the same participants that undergo an Anterior Cingulotomy (n=7) and a 
Vagus Nerve Stimulation (n=8) in Part Two. 
 
2.2  Methods 
2.2.1 Participants 
Fifteen clinically referred participants with chronic (>2yr) MDD (5 
male, 10 female) were tested.  All MDD participants were assessed by an 
experienced psychiatrist and met criteria for a diagnosis of DSM-IV MDE. 
Mean age of participants with MDD was 51.2 (SD 8.3) years and their IQ as 
measured with the NART - National Adult Reading Test (Nelson, 1982) was 
120.6 (SD 3.1). On the BDI-II - Beck Depression Inventory (Beck et al., 
1996) and the (17 item) HDRS17 - Hamilton Depression Rating Scale  
(Hamilton, 1960) the groups mean scores were 34.9 (SD 8.8) and 22.5 (SD 
5.0) respectively. All MDD participants were receiving antidepressant 
medication. Medication as total dose per day was: Phenelzine (60mg), 
Sertraline (200mg), Isocarboxazid (10mg), Venlafaxine (75-375mg), 
Trimipramine (150mg), Amitriptyline (350mg), Citalopram (20mg) and 
Tranylcypromine (30mg). Additional combination/ augmentation strategies 
were: Lithium carbonate (600-800mg), Quetiapine (400-750mg), 
Buproprion (300mg), Mirtazapine (45mg), Valproate Sodium (500mg), L-
Tryptophan (2-4 grams) and Chlorpromazine (75mg). Further, a total of 3 
participants were taking benzodiazepines, at a Diazepam dose-equivalent of 
10-30mg/ day. Two participants were taking hypnotics (Zolpidem and 
Zopiclone).  
 
2.2.1.1 Anterior Cingulotomy 
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Seven participants from the MDD group (6 female, 1 male) with a mean 
age of 50.0 years (SD 3.9 years), and a mean IQ of 120.4 (SD 7.6) 
underwent Anterior Cingulotomy29. Participants of both Anterior 
Cingulotomy and Vagus Nerve Stimulation groups were tested before 
surgical treatment and 1 year after. 
 
2.2.1.2 Vagus Nerve Stimulation 
The remaining eight participants from the MDD group (4 female, 4 
male) with a mean age of 51.8 years (SD 8.9 years), and a mean IQ of 122.9 
(SD 3.4) underwent surgical procedures to implant a Cyberonics VNS 
device30, which consist of a lithium battery fuelled generator, a lead wire 
system with electrodes, and an anchor tether to connect leads to the left 
vagus nerve. Participants of both Anterior Cingulotomy and Vagus Nerve 
Stimulation groups were tested before surgical treatment and 1 year after. 
 
2.2.1.3 Controls for Emotional Processing Tasks 
38 control participants without histories of MDD (14 male, 24 female) 
were tested. Mean age of the control participants was 50.9 (8.3) years, and 
their IQ was 121.7 (SD 5.7). Student t-tests showed no significant 
differences between groups for age (t=0.10, df=51, p=.92) and estimated 
pre-morbid intelligence (t=-0.90, df=51, p=.35). 
 
2.2.2 Tasks assessing Emotional Processing 
2.2.2.1 Ekman 60 Faces Test 
Faces are presented one at a time for 5 seconds each, and the participant 
is asked to decide which of the emotion (happiness, sadness, surprise, 
disgust, anger, and fear) best describes the facial expression shown. The 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
29 see section 1.3.3.3 
30 see section 1.3.3.2	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names of these six emotions are visible on the computer screen throughout 
the test. The order in which the emotion names are shown on the screen is 
randomized each time the test is given. Full details of the procedure can be 
found in the manual accompanying the FEEST (Young et al., 2002). 
The Ekman 60 Faces test contains photographs of the faces of 10 people 
from the Ekman and Friesen series (Ekman and Friesen, 1976). Ten pictures 
are used to test for each of six emotions (happiness, surprise, fear, sadness, 
disgust, and anger) making the test contains 60 total pictures. The pictures 
are presented in random order. The maximum score is 10 for each of the 6 
emotion categories. 
 
2.2.2.2 Emotion Hexagon 
The faces are presented one at a time for 5 seconds each, and the 
participant is asked to decide which of the emotion names (happiness, 
sadness, surprise, disgust, anger, and fear) best describes the facial 
expression shown. The names of these six emotions are visible on the 
computer screen throughout the test. The order in which the emotion names 
are shown on the screen are randomized each time the test is given. 
The Emotion Hexagon test uses photographic-quality morphed images 
of an individual’s face from the Ekman and Friesen series, which were 
prepared by blending different emotional facial expressions. The test set 
consists in 30 stimuli, comprising 5 morphed images for each of 6 emotions: 
happiness – surprise, surprise – fear, fear – sadness, sadness – disgust, 
disgust – anger, and anger – happiness, in proportions 90/10 (e.g., 90% fear 
+ 10% surprise), 70/30 (70% fear + 30% surprise), 50/50 (50% fear + 50% 
surprise), 30/70 (30% fear + 70% surprise), and 10/90 (10% fear + 70% 
surprise). The test contains 30 practice trials, followed by 5 test blocks. In 
each test block 30 images are presented in random order. For the purposes 
of scoring, the responses to the 50/50 morphed images (which are not 
usually identified as a particular emotion) and to the practice block trials are 
excluded, leaving a maximum score of 20 for each of the emotion. Data for 
this test is only included for Part One. 
 
Grant 49 
	  
2.2.2.3 Calder Emotional Numbers 
Recognition of vocally presented emotions was also assessed using the 
Emotional Numbers Test. 10 strings of numbers were spoken by an actor 
with a happy, fearful, sad, disgusted, or angry vocal intonation. This gives a 
total of 50 stimuli with a possible maximum of 10 for each of the five 
emotions. Stimuli were presented in pseudo-random order. The participants 
had to decide which of the 5 emotion labels best described the vocal 
intonation. 
2.2.2.4 Morgenstern Test 
The Morgenstern test assesses one’s ability to recognize and identify 
specific emotions associated with a voice sample (Sprengelmeyer et al., 
1996). Meaningless words were used to create a set of 10 different nonsense 
"sentences", each spoken by an actor with a happy, surprised, fearful, sad, 
disgusted, or angry vocal intonation. This gives a total of 60 stimuli with a 
maximum score of 10 for each of the six emotions. Stimuli were presented 
in pseudo-random order. As in the facial expression tasks, participants had 
to decide which of the 6 basic emotion labels best described the vocal 
intonation.  
 
2.2.2.5 Emotional Gestures 
2.2.2.5.1 Full/Point Light Movies 
Finally, we examined one’s ability to recognize emotions expressed by 
body language. Ten actors (5 male, 5 female) were asked to produce 
movements expressing 5 basic emotions: happiness, fear, sadness, disgust, 
or anger. These movements were recorded under two viewing conditions, a 
full light condition, in which the whole body of the acting person was 
visible, and a point light conditions. In the latter condition, 13 reflective 
stripes were attached to the major joints and the forehead of the actor. When 
presented, only the reflective strips are visible as moving patches against a 
black background (Atkinson et al., 2004). For each condition, there were 50 
short video clips with a length between 4.5 and 9 seconds and with 10 clips 
for each emotion. The clips were arranged in a fixed pseudo-random order 
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and shown to the participant’s one after the other. After each presentation, 
the participants had to decide which of the emotion names (happiness, fear, 
sadness, disgust, or anger) best described the emotion expressed by the 
actor.  The five emotion words were shown at the bottom of the screen. 
Responses were made verbally and noted by the examiner. 
 
 
2.3 Results 
2.3.1 Part One: Comparison of Controls vs. non-NMD treated MDD 
2.3.1.1 Tasks assessing Emotional Processing  
2.3.1.1.1 Ekman 60 Faces Test 
For the Ekman 60 tests a repeated measures ANOVA was performed 
with emotion (happiness, surprise, fear, sadness, disgust, and anger) as a 
within-subject factor, and group (MDD vs. control participants) as a 
between-subjects factor. The findings suggested a significant effect of 
emotion (F(5,255)= 27.16, P<.001). No significant group effect was seen 
(F(1,51)=2.99, p=.09), but there was a significant emotion x group interaction 
(F(5,255)=3.17, p<.01). To explore the interaction, independent t-tests were 
performed which showed no significant differences for happiness (t=-1.30, 
p=.19), surprise (t=-1.33, p=.19), fear (t=1.84, p=.07), sadness (t=.06, 
p=.96), and anger (t=.55, p=.59). The only exception was the recognition of 
disgust (t=3.31, p=.002), which was impaired in MDD as compared to 
controls. The degree of freedom for all t-tests performed was 51. Results are 
given in Figure 1.1 and Table 1.1.  
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Figure 1.1 
 
 
Table 1.1  
Controls MDD Ekman 60 
Mean Std. 
Deviation 
Mean Std. 
Deviation 
HAP 9.89 0.31 10.00 0.00 
SUR 8.84 1.13 9.27 0.80 
FEA 7.24 2.05 6.00 2.56 
SAD 8.03 1.57 8.00 1.41 
DIS 8.95 1.25 7.47 1.92 
ANG 8.11 1.77 7.80 1.97 
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2.3.1.1.2 Emotion Hexagon 
For the Emotion Hexagon test we performed a repeated measures 
ANOVA with emotion (happiness, surprise, fear, sadness, disgust, and 
anger) as a within-subject factor, and group (MDD vs. control participants) 
as a between-subjects factor. The findings suggested a significant effect of 
emotion (F(5,255)= 10.60, p<.001), a significant group effect (F(1,51)=5.35, 
p<.05), as well as a trend towards a significant emotion x group interaction 
(F(5,255)=2.17, p=.06). To explore the interaction, independent t-tests were 
performed which showed no significant differences for happiness (t= -.30, 
p=.77), surprise (t=-.01, p=.99), fear (t= .585, p=.56), and sadness (t= 1.94, 
p=.06). Recognition of disgust (t= 2.16, p=.04) and anger (t= 2.55, p=.01) 
were impaired in MDD as compared to controls. The degree of freedom for 
all t-tests performed was 51. Results are given in Figure 1.2 and Table 1.2.  
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Figure 1.2 
 
 
Table 1.2 
Controls MDD Emotion 
Hexagon 
Mean Std. 
Deviation 
Mean Std. 
Deviation 
HAP 19.50 1.03 19.60 1.30 
SUR 16.92 2.89 16.93 3.54 
FEA 16.39 3.09 15.80 3.91 
SAD 19.58 0.95 18.20 4.18 
DIS 18.00 2.48 15.40 6.38 
ANG 18.37 1.95 15.73 5.65 
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2.3.1.1.3 Calder Emotional Numbers 
For the Calder Emotional Numbers test a repeated measures 
ANOVA was performed with emotion (happiness, surprise, fear, sadness, 
disgust, and anger) as a within-subject factor, and group (MDD vs. control 
participants) as a between-subjects factor. The analysis gave a significant 
effect of emotion (F(4,204)= 4.78, p<.01), a significant group effect 
(F(1,51)=9.30, p<.01), but no significant emotion x group interaction 
(F(4,204)=1.98, p=.10). To explore the interaction, independent t-tests were 
performed which showed no significant differences for happiness (t= 1.38, 
p=.17), fear (t= .53, p=.60), and sadness (t= .77, p=.45). Recognition of 
disgust (t= 2.58, p=.01) and anger (t= 3.10, p=.003) were impaired in MDD 
as compared to controls. The degree of freedom for all t-tests performed was 
51. Results are given in Figure 1.3 and Table 1.3.  
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Figure 1.3 
 
 
Table 1.3 
Controls MDD Calder 
Emotional 
Numbers Mean Std. 
Deviation 
Mean Std. 
Deviation 
HAP 7.76 2.12 6.93 1.49 
FEA 7.50 1.41 7.27 1.53 
SAD 7.95 1.45 7.60 1.55 
DIS 7.21 1.65 5.60 2.85 
ANG 7.66 1.76 5.93 1.98 
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2.3.1.1.4 Morgenstern Test 
For the Morgenstern test a repeated measures ANOVA was 
performed with emotion (happiness, surprise, fear, sadness, disgust, and 
anger) as a within-subject factor, and group (MDD vs. control participants) 
as a between-subjects factor. We found a significant effect of emotion 
(F(5,255)= 69.29, p<.001), a significant group effect (F(1,51)=61.60, p=.21), and 
a significant emotion x group interaction (F(5,255)=6.28, p<.001). To explore 
the interaction, independent t-tests were performed which showed no 
significant differences for surprise (t=-1.62, p=.11), fear (t= 1.81, p=.08), 
sadness (t= -1.74, p=.09), disgust (t=.9, p=.34) and anger (t= -.60, p=.55). 
Recognition of happiness (t=3.85, p<.001) was impaired in MDD as 
compared to controls. The degree of freedom for all t-tests performed was 
51. Results are given in Figure 1.4 and Table 1.4.  
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Figure 1.4
 
 
Table 1.4 
Controls MDD Morgenstern 
Mean Std. 
Deviation 
Mean Std. 
Deviation 
HAP 5.08 2.02 2.73 1.94 
SUR 8.24 1.34 8.87 1.06 
FEA 7.18 1.77 6.20 1.82 
SAD 8.29 1.86 9.20 1.27 
DIS 6.03 1.95 5.40 2.53 
ANG 8.76 1.32 9.00 1.20 
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2.3.1.1.5 Emotional Gestures: Full Light Movies 
For the Full Light Movies test a repeated measures ANOVA was 
performed with emotion (happiness, surprise, fear, sadness, disgust, and 
anger) as a within-subject factor, and group (MDD vs. control participants) 
as a between-subjects factor. The analysis gave a significant effect of 
emotion (F(4,204)= 12.18, p<.001), a significant group effect (F(1,51)=17.62, 
p<.001), but no significant emotion x group interaction (F(4,204)=1.39, 
p=.24). To explore the interaction, independent t-tests were performed 
which showed no significant differences for happiness (t= 1.96, p=.06) and 
anger (t= 1.16, p=.25). Recognition of fear (t= 4.50, p<.001), sadness (t= 
2.20, p=.033), and disgust (t= 2.50, p=.016) were impaired in MDD as 
compared to controls. The degree of freedom for all t-tests performed was 
51. Results are given in Figure 1.5 and Table 1.5.  
Figure 1.5 
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Table 1.5 
Controls MDD Full Light 
Movies 
Mean Std. 
Deviation 
Mean Std. 
Deviation 
HAP 7.37 1.72 6.27 2.15 
FEA 8.76 1.34 6.53 2.20 
SAD 8.47 1.54 7.40 1.77 
DIS 6.55 1.67 5.07 2.55 
ANG 8.00 1.58 7.33 2.53 
 
 
2.3.1.1.6 Emotional Gestures: Point Light Movies 
For the Point Light Movies test we performed a repeated measures 
ANOVA with emotion (happiness, surprise, fear, sadness, disgust, and 
anger) as a within-subject factor, and group (MDD vs. control participants) 
as a between-subjects factor. The analysis gave a significant effect of 
emotion (F(4,204)= 16.91, p<.001), a significant group effect (F(1,51)=16.43, 
p<.001), but no significant emotion x group interaction (F(4,204)=0.94, 
p=.44). To explore the interaction, independent t-tests were performed 
which showed no significant differences for sadness (t= 1.96, p=.06) and 
anger (t= 1.92, p=.06). Recognition of happiness (t= 3.50, p<.001), fear (t= 
2.46, p=.02), disgust (t= 2.92, p=.005) were impaired in MDD as compared 
to controls. The degree of freedom for all t-tests performed was 51. Results 
are given in Figure 1.6 and Table 1.6.  
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Figure 1.6 
 
Table 1.6 
Controls MDD Point Light 
Movies 
Mean Std. 
Deviation 
Mean Std. 
Deviation 
HAP 7.45 1.50 5.80 1.66 
FEA 7.74 1.48 6.53 1.89 
SAD 7.97 1.39 7.13 1.46 
DIS 6.11 2.00 4.20 2.48 
ANG 7.63 1.63 6.60 2.06 
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2.3.1.2 Part One Summary Table 
 Happiness Surprise Fear Sadness Disgust Anger Total 
Score 
Ekman 60     √ (p=.002)   
Emotion 
Hexagon 
    √ (p=.036) √ 
(p=.014) 
√ 
(p=.023) 
Calder 
Emotional 
Numbers 
    √ (p=.013) √ 
(p=.003) 
√ 
(p=.003) 
Morgenstern test √ (p=.00033)       
Full Light   √ 
(p=.00
0039) 
√ (p=.033) √ (p=.016)  √ 
(p=.0001
2) 
Point Light √ (p=.001)  √ 
(p=.01
7) 
 √ (p=.005)  √ 
(p=.0001
7) 
√ = MDD Group made significantly more errors than Control Group 
 
 
 
 
 
2.3.2 Part Two: Comparison pre- and post-NMD treatment 
2.3.2.1 Tasks assessing Emotional Processing  
2.3.2.1.1 Ekman 60 Faces Test 
For the pre-post comparison of the Ekman 60 Faces Test results, a 
repeated measures ANOVA was performed with pre-and post surgery, as 
well as emotion (happiness, fear, sadness, disgust, and anger) as within-
subject factors, and group (VNS vs. ACING participants) as a between-
subjects factor. The analysis gave a significant effect of emotion (F(5,65)= 
16.22, p<.001), no significant group (F(1,13)=0.11, p=.75), and no significant 
pre-post effect (F(1,65)= 0.05, p=.82). There was a significant pre-post x 
group interaction (F(1,65)= 4.98, p<.05), qualified by a significant pre-post x 
group x by emotion interaction (F(5,65)= 2.64, p<.05). The emotion x group 
(F(5,65)= 0.45, p=.81), and the emotion x pre-post surgery interactions 
(F(5,65)= .11, p=.37) were not significant. To explore the significant pre-post 
x group x by emotion interaction, paired t-tests were performed separately 
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for each clinical group, comparing the performance before and after surgery 
for single emotions. 
2.3.2.1.1.1 ACING 
There was no significant change for all emotions in the ACING group. 
The paired t-tests gave the following results: happiness (no variance), 
surprise (t=1.86, p=.11), fear (t=1.20, p=.28), sadness (t=1.00, p=.36), 
disgust (t=-.28, p=.79), and anger (t=-0.66, p=.54). The degree of freedom 
for all t-tests performed was 6. See Table 2.1.1 for means and standard 
deviations. Results are given in Figure 2.1.1 and Table 2.1.1.  
Figure 2.1.1 
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Table 2.1.1 
Pre-Surgery Post-Surgery Ekman 60 
Mean Standard 
Deviation 
Mean Standard 
Deviation 
HAPPY 10.00 0.00 10.00 0.00 
SURPRISE 9.71 0.49 7.29 3.30 
FEAR 6.57 3.05 4.71 2.81 
SADNESS 8.43 1.13 7.71 1.50 
DISGUST 8.00 0.82 8.14 1.77 
ANGER 7.43 2.57 8.14 1.57 
 
2.3.2.1.1.2 VNS 
The VNS group’s disgust recognition improved significantly, and there 
was a trend towards significance for recognition of fearful faces. 
Recognition of all other emotions showed no significant changes. The paired 
t-tests gave the following results: happiness (t=1.0, p=.35), surprise (t=-0.51, 
p=.63), fear (t=-1.94, p=.09), sadness (t=-1.31, p=.23), disgust (t=-2.76, 
p=.03), and anger (t=-0.64, p=.54). The degree of freedom for all t-tests 
performed was 7. Results are given in Figure 2.1.2 and Table 2.1.2. 
 
 
 
 
 
 
 
 
 
Grant 64 
	  
Figure 2.1.2 
 
 
Table 2.1.2 
Pre-Surgery Post-Surgery Ekman 60 
Mean Standard 
Deviation 
Mean Standard 
Deviation 
HAPPY 10.00 0.00 9.75 0.71 
SURPRISE 8.88 0.84 9.13 0.83 
FEAR 5.50 2.14 7.25 1.67 
SADNESS 7.63 1.60 8.50 0.93 
DISGUST 7.00 2.51 8.25 2.05 
ANGER 8.13 1.36 7.63 2.07 
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2.3.2.1.2 Calder Emotional Numbers 
For the pre-post comparison of the results from the Calder Emotional 
Numbers Test, a repeated measures ANOVA with pre-and post surgery and 
emotion (happiness, fear, sadness, disgust, and anger) as within-subject 
factors, and group (VNS vs. ACING participants) as a between-subjects 
factor was performed. The analysis gave a significant effect of emotion 
(F(4,65)= 3.54, p<.05), a trend towards significance for the group effect 
(F(1,13)=3.34, p=.09), and no significant pre-post effect (F(1,52)= 0.32, p=.58). 
The pre-post x group interaction (F(1,52)= 2.92, p=.11) and the pre-post x 
group x by emotion interaction (F(4,52)= 0.91, p=.47) were not significant. 
The emotion x group (F(4,52)= 0.38, p=.82), and the emotion x pre-post 
surgery interactions (F(4,52)= 0.38, p=.8) were also not significant. See Table 
2.3.1 and Table 2.3.2 for mean and standard deviation. 
2.3.2.1.2.1 ACING 
Table 2.3.1 
Pre-Surgery Post-Surgery Calder                       
Emotional  
Numbers 
Mean Standard 
Deviation 
Mean Standard 
Deviation 
HAPPY 6.86 0.90 6.29 2.69 
FEAR 6.86 1.77 6.43 1.99 
SADNESS 7.43 1.51 7.29 2.56 
DISGUST 4.71 3.15 4.86 2.79 
ANGER 5.86 2.34 5.29 2.81 
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2.3.2.1.2.2 VNS 
Table 2.3.2 
Pre-Surgery Post-Surgery Calder                               
Emotional          
Numbers 
Mean Standard 
Deviation 
Mean Standard 
Deviation 
HAPPY 7.00 1.93 7.75 1.67 
FEAR 7.63 1.30 7.75 1.04 
SADNESS 7.75 1.67 7.88 0.64 
DISGUST 6.38 2.50 6.75 2.12 
ANGER 6.00 1.77 7.75 2.12 
 
2.3.2.1.3 Morgenstern Test 
For the pre-post comparison of the results from the Morgenstern Test, a 
repeated measures ANOVA with pre-and post surgery and emotion 
(happiness, surprise, fear, sadness, disgust, and anger) as within-subject 
factors, and group (VNS vs. ACING participants) as a between-subjects 
factor was performed. The analysis gave a significant effect of emotion 
(F(5,60)= 48.52, p<.001), no significant group effect (F(1,12)=1.40, p=.26), and 
no significant pre-post effect (F(1,60)= 1.91, p=.19). The pre-post x group 
interaction (F(1,60)= 2.43, p=.15) and the pre-post x group x by emotion 
interaction (F(5,60)= 1.57, p=.18) were not significant. The emotion x group 
(F(5,60)= 0.47, p=.80), and the emotion x pre-post surgery interactions 
(F(5,60)= 0.91, p=.48) were also not significant. See Table 2.4.1 and Table 
2.4.2 for means and standard deviations. 
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2.3.2.1.3.1 ACING 
Table 2.4.1 
Pre-Surgery Post-Surgery Morgenstern 
Mean Standard 
Deviation 
Mean Standard 
Deviation 
HAPPY 3.17 2.31 1.00 1.67 
SURPRISE 9.00 0.89 7.00 1.67 
FEAR 6.67 1.86 6.17 3.25 
SADNESS 9.50 1.23 8.67 2.42 
DISGUST 4.67 2.25 4.66 1.21 
ANGER 9.17 1.17 8.33 1.21 
 
2.3.2.1.3.2 VNS 
Table 2.4.2 
Pre-Surgery Post-Surgery Morgenstern 
Mean Standard 
Deviation 
Mean Standard 
Deviation 
HAPPY 2.50 1.85 3.25 3.15 
SURPRISE 9.00 1.07 8.88 1.36 
FEAR 6.25 1.50 7.13 1.25 
SADNESS 9.25 1.17 9.38 1.77 
DISGUST 6.00 2.88 5.63 1.69 
ANGER 9.00 1.31 8.13 1.13 
 
2.3.2.1.4 Emotional Gestures 
The Emotional Gestures tests include both the Full and Point Light 
Movies. For the pre-post comparison of the results from the Emotional Full 
and Point Light Movies, repeated measures ANOVAs with pre-and post 
surgery and emotion (happiness, fear, sadness, disgust, and anger) as within-
subject factors, and group (VNS vs. ACING participants) as a between-
subjects factor was performed. 
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2.3.2.1.4.1 Full Light Movies 
The analysis gave a significant effect of emotion (F(4,52)= 4.95, p<.01) 
and a borderline pre-post effect (F(1,52)= 4.57, p=.05). The pre-post x group 
interaction (F(1,52)= 3.04, p=.11), group effect (F(1,13)=5.77, p=.26),  and the 
pre-post x group x by emotion interaction (F(4,52)= 0.32, p=.86) were not 
significant. The emotion x group (F(4,52)= 1.20, p=.32), and the emotion x 
pre-post surgery interactions (F(4,52)= 0.77, p=.55) were also not significant. 
See Table 2.5.1 and Table 2.5.2 for means and standard deviations. 
2.3.2.1.4.1.1 ACING 
Table 2.5.1 
Pre-Surgery Post-Surgery Full Light 
Movies Mean Standard 
Deviation 
Mean Standard 
Deviation 
HAPPY 5.86 1.86 6.29 2.75 
FEAR 6.29 2.43 7.00 1.73 
SADNESS 7.43 1.27 7.29 2.50 
DISGUST 4.29 2.98 3.88 3.44 
ANGER 6.00 3.11 6.00 2.71 
 
2.3.2.1.4.1.2 VNS 
Table 2.5.2 
Pre-Surgery Post-Surgery Full Light 
Movies Mean Standard 
Deviation 
Mean Standard 
Deviation 
HAPPY 6.63 2.45 7.50 1.93 
FEAR 6.75 2.12 9.00 0.53 
SADNESS 7.38 2.20 8.25 0.89 
DISGUST 5.75 2.05 7.13 2.85 
ANGER 8.50 1.07 8.75 1.83 
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2.3.2.1.4.2 Point Light Movies 
The ANOVA gave a significant effect of emotion (F(4,52)= 9.64, p<.001), a 
significant group effect (F(1,13)=13.13, p=.01), and a non-significant pre-post 
effect (F(1,52)= 1.10, p=.31). The pre-post x group interaction (F(1,52)= 0.04, 
p=.87) and the pre-post x group x by emotion interaction (F(4,52)= 0.08, p=.99) 
were not significant. The emotion x group (F(4,52)= 1.12, p=.36), and the 
emotion x pre-post surgery interactions (F(4,52)= 0.43, p=.79) were also not 
significant. See table 2.6.1 and Table 2.6.2 for means and standard deviations. 
2.3.2.1.4.2.1 ACING 
Table 2.6.1 
Pre-Surgery Post-Surgery Point Light 
Movies Mean Standard 
Deviation 
Mean Standard 
Deviation 
HAPPY 5.14 1.57 4.86 2.61 
FEAR 5.71 1.98 6.43 3.10 
SADNESS 6.43 1.72 6.86 2.12 
DISGUST 2.71 1.80 2.86 2.27 
ANGER 5.29 2.06 5.29 2.63 
 
2.3.2.1.4.2.2 VNS 
Table 2.6.2 
Pre-Surgery Post-Surgery Point Light 
Movies Mean Standard 
Deviation 
Mean Standard 
Deviation 
HAPPY 6.38 1.60 6.38 1.30 
FEAR 7.25 1.58 8.00 1.31 
SADNESS 7.75 0.89 7.88 1.81 
DISGUST 5.50 2.33 6.10 2.42 
ANGER 7.75 1.28 7.75 1.28 
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2.3.2.2 Part Two Summary Table 
 Happiness Surprise Fear Sadness Disgust Anger 
Ekman 60       
ACING       
VNS     + 
(p=.03) 
 
Calder 
Emotional 
Numbers 
      
ACING       
VNS       
Morgenstern 
test 
      
ACING       
VNS       
Full Light       
ACING       
VNS       
Point Light       
ACING       
VNS       
+ = Emotion recognition improved significantly one-year post surgery compared to pre 
surgery 
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2.4  Discussion 
2.4.1 Introduction 
The discussion section focuses on MDD as a neuropsychological 
syndrome where physical neuroanatomical changes modulate cerebral 
dysfunction. The clinical symptoms of MDD are directly related to 
disordered processing among complex neural circuits affected by these 
physical abnormalities (Mayberg, 2009). The aetiology of the dysfunction of 
abnormal neural substrates is not completely understood, but converging 
evidence agrees that altered synthesis, secretion and concentrations of 
fundamental neurotransmitters, hormones, and growth factors can trigger 
atrophic changes to specific neural structures—for example, 
hypercortisolemia causes atrophy to hippocampal neurons. It also seems that 
certain individuals have lower genetic thresholds for stress and thus a higher 
risk of developing MDD (Caspi, 2003). Namely, the affected structures are 
the dorsomedial and dorsolateral prefrontal cortices, as well as the limbic 
regions including the subgenual cingulate cortex, amygdala, insula, 
ventrolateral prefrontal cortex, ventral striatum, and thalamus (Phillips, 
2003). These affected brain structures disrupt neural networks that are 
crucial for normal emotional processing abilities (Phillips, 2003). Scores on 
emotional processing tasks have been observed to be lower in patients 
experiencing depressive episodes (Morris, 2009; Douglas, 2010).  
The aim of Part One of the discussion is to examine whether a group of 
patients with chronic treatment-resistant MDD showed deficits in emotional 
processing compared to healthy controls, as measured by the results of tasks 
assessing emotional processing. This will serve as a baseline for whether the 
MDD group has measureable deficits in emotional processing before 
surgical intervention. Hypotheses and speculations may also be made to 
which brain areas are most affected in our patient group based upon their 
abilities to recognize specific emotions. 
Part Two discusses the effects of therapeutic neurosurgical interventions 
(ACING and VNS) on chronic treatment-resistant MDD by comparing the 
results of emotional processing tasks administered before and after surgery. 
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Statistically significant side effects of ACING and VNS procedures will be 
considered in order to determine the effects of NMD on emotion processing 
and what neural side effects may be occurring after surgery. The 
independent group t-tests performed are interpreted as changes from 
baseline, more specifically improvement after surgery as compared to 
before.  
It is important to note that as the number of t-tests increase, so does the 
likelihood of type 1 or alpha errors. The study is at risk for experimentwise 
error, or an increased type 1 error rate. To protect against inflating Type I 
Error rate in the individual t-tests, we first performed a repeat measure 
ANOVA analysis. 
 
2.4.2 Part One 
The MDD group had decreased ability to recognize at least one 
emotional expression (e.g., fear, sadness, and anger) in each of the six tests 
administered (Ekman 60 Faces Test, Emotion Hexagon, Calder Emotional 
Numbers, Morgenstern Test, Full Light Movies and Point Light Movies) as 
compared to healthy controls. The results show that the control group was 
better at processing emotions than the MDD group. Overall, the depressed 
group showed decreased emotion recognition in 12 out of the total 33 
emotional expressions presented. Deficits in disgust recognition were most 
severe and were noticed in five of the six tests administered. Anger, fear and 
happiness recognition were each noticed to be decreased in two out of the 
six tests administered. Surprise recognition was affected in one of the six 
tests administered. 
t-test and repeated-measures ANOVA results show recognition of 
disgust was the most affected by MDD. MDD patients presented a 
significant decrease compared to controls in their ability to recognize the 
emotion of disgust on five out of the six tests administered—specifically on 
the Ekman 60 Faces Test, Emotion Hexagon, Calder Emotional Numbers, 
Full Light Movies and Point Light Movies. Both tasks measuring the ability 
to identify emotional facial expressions, the Ekman 60 Faces Test and 
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Emotion Hexagon test, demonstrated decreased disgust recognition. Both 
tests measuring the ability to identify emotional body language and gestures, 
the Full Light Movie and Point Light Movie tests, showed decreased disgust 
recognition as well. One of the two tests measuring the ability to identify 
emotional voices and sounds, the Morgenstern Test, also presented 
decreased disgust recognition. The fact that disgust recognition was 
impaired across tests that measured emotion-processing abilities using 
emotional faces, voices, and gestures suggests that this deficit impairs 
disgust recognition across multiple modalities of perception.  
Speculatively, deficits of disgust recognition in the MDD group, as 
compared to healthy controls, suggest possible involvement of certain neural 
structures in MDD. Previous studies have shown that the temporal and 
frontal gyri, insula, globus pallidus and amygdala are activated in the 
recognition of disgust (Murphy, 2003; Fusar-Poli, 2008). More specifically, 
disgust recognition has been linked to the insular cortex (Calder 2000; 
Hennenlotter et al., 2004; Kipps et al., 2007; Phillips et al., 1997; 
Sprengelmeyer et al., 1998; Wicker et al., 2003). This suggests that this 
structure may be dysfunctional in MDD, a finding consistent with research 
performed by Sprengelmeyer et al. (2011). In the same study, significant 
grey matter reductions in the insular cortex were found in the MDD 
participants. Sprengelmeyer et al. (2010) showed that the ability to 
recognize the facial expression of disgust was significantly correlated with 
volumetric reduction in the anterior insula. 
The deficit in disgust recognition noted in the MDD group agrees with 
the findings of Douglas et al. (2010). His study used similar methods, as he 
compared the ability of 68 MDD patients to recognize facial expressions 
compared to controls. The MDD group was significantly impaired in 
recognizing the facial expression of disgust. This disgust deficit has been 
noticed in people with Huntington’s disease and unmedicated patients with 
Parkinson’s disease as well (Sprengelmeyer et al., 1996, 2003). This deficit 
may be explained by the fact that patients who carry the Huntington's 
disease gene show significantly higher rates of depressive symptoms as 
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compared to controls (Julien et al., 2007). Furthermore, smaller insular 
cortex volumes are associated with onset of symptoms in Huntington’s 
disease (Thieben et al., 2002). The deficit in disgust recognition from Part 
One possibly agrees with other studies in that the insular cortex is affected 
by MDD and may be associated with major symptoms of the disorder 
(Sprengelmeyer et al., 2011). 
The t-test and one way ANOVA findings of Part One also show that 
MDD patients had decreased ability in recognizing the emotion of fear. 
Decreased fear recognition was noticed in both tests measuring the ability to 
identify emotional body language and gestures, the Full Light Movie and 
Point Light Movie tests. Speculatively, deficits in fear recognition suggest 
possible involvement of certain neural structures in MDD. Fear recognition 
is associated most strongly with the amygdala, as lesions to the amygdala 
lead to impaired fear recognition (Adolphs et al., 1994). Volumetric grey 
matter reductions of the amygdala in the MDD brain have been observed 
(Bremner, 2000; Caetano, 2004; Hastings, 2004; Monkul, 2007; 
Sprengelmeyer et al. 2011). Post mortem studies also show reduced glial 
cell density in the amygdalas of reported depressed individuals (Bowley, 
2002). This suggests that the MDD group studied in Part One may have 
experienced pathological changes to their amygdalae that has lead to deficits 
in fear recognition. Furthermore, one may propose that because of this, the 
amygdala is affected by MDD and may be associated with major symptoms 
of the disorder. 
A decreased ability in anger recognition was observed in two of the six 
tasks administered to the MDD group. Specifically, these deficits occurred 
on a task measuring ability to recognize emotional faces, the Emotion 
Hexagon test, as well as in a test measuring ability to identify vocally 
presented emotion, the Calder’s Emotional Numbers Test. The ventral 
striatum, specifically the nucleus accumbens, has been associated with the 
facial expression of anger, as lesions to this area create anger recognition 
deficits (Calder et al., 2004). Converging findings from 106 PET and fMRI 
studies show that lateral OFC activity was noticed in more studies dealing 
with anger than any other emotion (Murphy, 2003). Amygdala-lesioned 
Grant 75 
	  
individuals also have deficits in recognizing anger, but less severe than their 
deficits in fear recognition (Adolphs et al., 1995; Calder et al., 1996; 
Sullivan and Ruffman, 2004). Therefore, the deficits in fear and anger 
observed in the MDD group may be at least partially due to abnormal 
function of the amygdala. Furthermore, abnormalities in both the nucleus 
accumbens and OFC could explain the deficit in anger recognition observed 
in the MDD group. This may suggest the nucleus accumbens and OFC are 
affected by MDD and may be associated with major symptoms of the 
disorder. 
Decreased happiness recognition was observed in two of the six tasks 
administered: specifically in a task-measuring ability to recognize emotional 
body language, the Point Light Movie Test, as well as in a test measuring 
ability to identify vocally presented emotion, the Morgenstern Test. MDD 
patients showed decreased ability in recognizing the emotion of sadness in 
one out of the six studies performed. Decreased sadness recognition was 
observed in a task measuring ability to recognize emotional body language 
(Full Light Movie Test). Surprise recognition was unaffected for the MDD 
group across all six tests. Neural structures associated with the recognition 
of happiness, sadness, or surprise, have not yet been isolated (Murphy, 
2003).  
Finally, it is important to note that clinically depressed individuals have 
impaired concentration, memory, and attention (Delgado, 2009). Patients 
with MDD also have slowed thought process (Giacobbe, 2009). The pattern 
of results could be due to the fact that depressed patients are less motivated 
and do not stay on task. What appears to be decreased recognition of a 
specific emotion across the MDD group may in fact be an artefact of 
decreased motivation and impaired concentration among these individuals. 
2.4.3 Part Two 
Upon remission of depressive symptoms, pathological brain activation in 
the amygdala, ACC, and OFC has been noticed to revert to levels expected 
in healthy individuals (Stuhrmann, 2011; Mayberg, 2009). The treatment 
options that are explored in Part Two are the ACING and VNS. Data are not 
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available as to whether or not the individual patients reached remission after 
treatment, but we can measure their response to surgery as measured by 
their performance on emotional processing tasks.  
After undergoing a VNS for therapeutic intervention for chronic, 
treatment-resistant MDD, patients showed improvements in emotion 
recognition, as compared to their pre-surgical results. The VNS one-year 
post-surgery scores on the Ekman 60 Faces task showed improvements in 
disgust recognition, compared to pre-surgery scores. VNS is targeting 
regions associated with MDD. The vagus nerve has connections to the 
insular and cingulate cortices, as well as the limbic and paralimbic structures 
(Bachman, 1977; Nahas, 2006). Increased cerebral blood flow to the insular 
cortices has been witnessed after VNS surgery (Henry, 1998). Increased 
blood perfusion to the insular cortex provided by VNS may return insular 
cortex function back to that of healthy individuals. This would explain the 
improvements in disgust recognition. However, increased cerebral blood 
flow also occurs in the rostral and dorsal-central medulla, right postcentral 
gyrus, hypothalami, thalami, and cerebellar hemispheres after VNS surgery, 
and decreased cerebral blood flow occurs in the hippocampus, amygdala, 
and posterior cingulate gyri following VNS surgery (Henry, 1998).  
2.4.4 Conclusion 
Findings in Part One and Two are consistent with previous research in 
which impairments in the recognition of emotional facial expressions in the 
depressed population are studied (Douglas, 2010). This study shows that 
deficits in emotional voice and gesture processing likewise exist in the 
MDD population, as compared to healthy controls. Disgust recognition was 
most severely affected in the MDD group, a finding convergent with 
previous research (Douglas et al., 2010; Sprengelmeyer et al., 2011) 
suggesting that the insular cortex is affected by MDD and may be associated 
with major symptoms of the disorder. Fear and anger recognition were also 
affected in the MDD group, but not as severely as disgust. Speculatively, 
these deficits propose that the amygdala, nucleus accumbens, and the OFC 
are affected by MDD, and may be associated with major symptoms of the 
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disorder as well. However, it is also possible that an integrated system able 
to code for all emotions is being affected. Volumetric or metabolic 
abnormalities to one neural substrate may inhibit a network responsible for 
mood and emotion regulation (Maclean, 1993; Murphy, 2003; Phillips, 
2003).  
Patients who underwent VNS for therapeutic intervention of chronic, 
treatment-resistant MDD showed improvement in emotional processing 
abilities in regards to disgust after surgical intervention as compared to their 
abilities before neurosurgery. In fact, disgust recognition that was 
significantly better recognized one year post VNS surgery was also the 
emotion that showed significant deficits among the MDD group in Part One. 
More specifically, disgust recognition on the Ekman 60 was significantly 
decreased in the MDD group compared to controls, and disgust recognition 
on the Ekman 60 was significantly improved one-year post VNS surgery. It 
is of particular interest that disgust recognition improved after VNS, as this 
was the most affected emotion in the MDD group from Part One. As the 
insula, OFC, nucleus accumbens and amygdala are responsible for the 
recognition of disgust, it seems that the function, and therefore possibly the 
structure, of these areas are restored one year after VNS. Perhaps the 
increased cerebral blood flow post VNS to brain areas proposed to be 
involved in the pathogenesis MDD may induce neurogenesis in these areas. 
This is purely speculative, but as neurogenesis in the hippocampus has been 
measured after administration of SSRI medications (Banasr, 2006; Schmidt, 
2007), it may not be far fetched to think this may be the case. 
The ANOVA results show no consistent impact of surgery as measured 
by improvement in scores on emotional tasks. Specifically, the ANOVA, as 
shown in the results, suggested no consistent improvement across all tests 
administered. The t-tests are to be interpreted as a change in baseline in 
score on emotion processing tasks from before surgery to one-year post 
surgery. However, the t-tests showed significant improvement on a few 
tests. This leads us to two speculative hypotheses. Firstly, the possibility that 
the surgeries were not effective, as consistent improvement was not seen 
across all tests administered. Secondly, the select t-test results emphasize a 
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need for further research meant to analyze the equivalency of the emotion 
tests administered. The latter is worthy of research as the tests used 
implement 3 very different interpretation of emotion: facial expression 
(Ekman 60 Faces, Emotion Hexagon), emotional voices (Calder, 
Morgenstern), and emotional body language (Full and Point Light Movies). 
While the lack of consistent improvement across all tests administered could 
suggest the surgeries were not effective, it also raises the query that it may 
not be possible to measure the efficacy of neurosurgery using 6 emotion 
processing tasks that require the patient to interpret 3 different 
representations of an emotion. The possibility exists that the results of the 
analysis would have been more consistent if tasks assessing only one 
modality (facial expression, voice, body language) had been utilized.  
 
2.4.4.1 Further Research and Potential Limitations  
Potential limitations exist in the study design. It has been shown that 
pathologic neuroanatomical changes associated with MDD can manifest 
differently with regards to gender (Frodl, 2002; Hastings, 2004; Lacerda, 
2004). Of the 15 MDD patients included there was a 10:5 female to male 
ratio, which was analyzed in Part One. The VNS group had a 4:4 ratio, and 
the ACING group had a 6:1 ratio. There is a large gender discrepancy in the 
ratios, which might influence performance on the tests. Repeating the 
methods of this study with all male or all female groups may allow for more 
reliable and reproducible results. 
Another limitation is the unique medication history of each patient, 
which differs substantially within the MDD group. It has been shown that 
medications can have unique side effects that alter one’s emotion-processing 
abilities (Fu, 2004). Decreased ability to recognize disgust has also been 
associated with citalopram administration in healthy controls (Harmer, 
2004). This is significant as citalopram was being administered to a few of 
the MDD participants of this study during the time of testing. Furthermore, 
other serotonergic antidepressants with similar mechanisms of action as 
citalopram were being administered as well. Deficits in emotion processing 
noticed in the MDD group may be due to MDD itself, or may be due to the 
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side effects of medication taken by the MDD group (Harmer, 2004). 
Medications can also have an effect on volumes of neuroanatomical 
structures that are important in emotion processing (Vythilingham, 2004). 
Repeating the methods of this study with a group taking the same 
medications or preferably (but unrealistically) without medications would 
eliminate potential confounders. 
Potential order effects could also be present in Part Two of the study. 
Specifically, upon taking the same tests twice (pre and one year post 
surgery) it is possible that a certain degree of practice may exist. This may 
lead to artificially increased scores one year post. A fatigue effect may also 
be present, in that participants may become bored or tired when taking the 
tests thus creating a decline in performance (Cozby, 2009). 
Further study would require information on whether or not the patients 
that underwent NMD reached remission from their depressive symptoms. If 
data were available as to whether or not individuals reached remission of 
clinical symptoms after their respective NMD, it would be possible to 
examine changes in emotional recognition in order to determine whether 
these changes may reflect objective markers of treatment outcome in MDD.  
Furthermore, studies should include several observations over a longer 
time span in order to check the validity of the data. For example, after 
surgical intervention TRD patients should perform behavioral tests two 
times per year for 10 years. 
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